---
title: "VK2735 in Chronic weight management: Product information and disease description"
description: "Formulary evidence on VK2735 in Chronic weight management: Product information and disease description. Covers Product description and Place of product in therapy. 298 evidence topics quoted from 147 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Regulatory status: Submission planned; NDA planned after VANQUISH phase 3 data expected in the second half of 2027

> “In addition, as a company, we have not previously filed NDAs with the FDA or filed similar applications with other foreign regulatory agencies.”

Source: [Viking Therapeutics Form 10-Q third quarter (2026)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526436432/vktx-20260930.htm)

> “If we can put together something that might be suitable for submission with the initial NDA, we would do that.”
> “It's possible we might be able to incorporate something in the initial filing.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

> “VK2735 Subcutaneous: VANQUISH Phase 3 Overview”
> “Data Expected 2H27”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “VANQUISH Phase 3 trials in obesity and T2D fully enrolled with data expected in 2H27”

Source: [Viking Therapeutics maintenance study presentation (2026)](https://ir.vikingtherapeutics.com/image/Maintenance+Study+Presentation.pdf)

> “During the third quarter, both VANQUISH studies continued to advance on track. The company expects these studies to be completed in 2027.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-2.1.1-2"></a>

##### Launch: Anticipated about two and a half years after October 2026

> “We have a pretty solid commercial team, especially given that we're 2 and a half years out from potential launch.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

> “these resources will support the company's growing commercial operations, infrastructure and plans as it prepares for the potential commercial launch of VK2735.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-2.1.1-3"></a>

##### Subcutaneous formulation: FDA Type C meeting and end-of-phase 2 meeting before phase 3

> “During the second quarter, Viking received written responses to a U.S. Food and Drug Administration (FDA) Type C meeting packet, submitted to the agency earlier in the quarter.”
> “The company has scheduled an End-of-Phase 2 meeting with the FDA during the fourth quarter, which will help inform next steps for the Phase 3 program.”

Source: [Viking Therapeutics third quarter 2024 results release (2024)](https://ir.vikingtherapeutics.com/2024-10-23-Viking-Therapeutics-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Corporate-Update)

> “In the fourth quarter of 2024, the company completed an End-of-Phase 2 meeting with the FDA and received feedback on the proposed Phase 3 plans as well as the overall development program for VK2735.”

Source: [Viking Therapeutics fourth quarter 2024 results release (2025)](https://ir.vikingtherapeutics.com/2025-02-05-Viking-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2024-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-2.1.1-4"></a>

##### Subcutaneous formulation: VANQUISH phase 3 program initiation and enrollment

> “today announced the initiation of the VANQUISH Phase 3 clinical program for VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.”

Source: [Viking Therapeutics VANQUISH initiation release (2025)](https://ir.vikingtherapeutics.com/2025-06-25-Viking-Therapeutics-Announces-Initiation-of-Phase-3-Obesity-Clinical-Program-with-GLP-1-GIP-Agonist-VK2735)

> “Based on the positive findings from the Phase 2 VENTURE study, and subsequent feedback from the U.S. Food and Drug Administration (FDA), the company advanced the subcutaneous formulation of VK2735 into Phase 3 development, initiating the VANQUISH Phase 3 registration program in June of last year.”
> “The VANQUISH-1 study enrolled approximately 4,500 patients within approximately five months of initiation. The VANQUISH-2 study enrolled approximately 1,000 patients within approximately 9 months of initiation.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-2.1.1-5"></a>

##### Subcutaneous formulation: VANQUISH extension studies and timing of a supplemental application

> “Following completion of the 78-week treatment period in both VANQUISH studies, participants are eligible to enroll in extension studies, enabling them to continue their treatment for up to an additional 52 weeks.”
> “In addition, the VANQUISH-1 extension study will include certain less-frequent dosing regimens, including every-other-week and monthly administration. The company anticipates the results of the extension studies to be available in 2028.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “I'd say it's probably more likely that it would be a supplement later, but we don't know that for sure at this point.”
> “But it seems more likely that the VANQUISH extension data would be sort of a standalone package that would be a supplement later.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-2.1.1-6"></a>

##### Oral formulation: end-of-phase 2 meeting with the FDA

> “Viking held an end-of-Phase 2 meeting with the FDA to discuss potential next steps for oral VK2735.”

Source: [Viking Therapeutics fourth quarter 2025 results release (2026)](https://ir.vikingtherapeutics.com/2026-02-11-Viking-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2025-Financial-Results-and-Provides-Corporate-Update)

> “As far as the oral end-of-Phase II and the subQ end-of-Phase II, we're not going to get into the details of the discussions, but I'd say the feedback was consistent with what we heard from the end-of-Phase II for the subQ formulation.”

Source: [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/)

> “The FDA, we had an end-of-phase II meeting in the fourth quarter last year, and the FDA they pointed out risks going from phase II to phase III, but they were okay with it.”

Source: [Viking Therapeutics Jefferies conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/678533-jefferies-global-healthcare-conference-2026/)

<a id="topic-2.1.1-7"></a>

##### Oral formulation: SUNRISE phase 3 program initiation and expected data timing

> “today announced the initiation of the SUNRISE Phase 3 clinical program for oral VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

> “VK2735 Oral: SUNRISE Phase 3 Overview”
> “Data Expected 2028”
> “Initiated 4Q26”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-2.1.1-8"></a>

##### Development history: first clinical studies of each formulation

> “In January 2022, we announced the initiation of a Phase 1 SAD and MAD clinical trial of VK2735.”
> “In March 2023, we announced the initiation of a Phase 1 clinical study to evaluate a novel oral formulation of VK2735.”

Source: [Viking Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526046876/vktx-20251231.htm)

<a id="topic-2.1.1-9"></a>

##### Expedited program designations

No evidence found.

<a id="topic-2.1.1-10"></a>

##### Patent estate for the GLP-1 agonist program

> “As of September 30, 2026, for our GLP-1 program, we own four U.S. patents, additional patents in certain foreign jurisdictions, three PCT applications, and several patent applications in the U.S. and certain foreign jurisdictions.”

Source: [Viking Therapeutics Form 10-Q third quarter (2026)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526436432/vktx-20260930.htm)

| Subject matter | Pending applications | Issued patents | Nominal patent term |
| --- | --- | --- | --- |
| GLP-1 agonists, as of December 31, 2025 | “113” | “13” | “2042-2045” |

Source: [Viking Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526046876/vktx-20251231.htm)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Viking Therapeutics

> “Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2026”
> “VK2735 is a wholly owned long-acting dual agonist of the glucagon like peptide-1, or GLP-1 receptor, and the glucose dependent insulinotropic polypeptide, or GIP receptor, in development for the potential treatment of obesity and other metabolic disorders.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “Viking retains ownership of all global rights to VK2735 under the agreement and expects to maintain standard pharmaceutical product margins.”

Source: [Viking Therapeutics CordenPharma agreement release (2025)](https://ir.vikingtherapeutics.com/2025-03-11-Viking-Therapeutics-Signs-Broad-Manufacturing-Agreement-With-CordenPharma-to-Support-Commercialization-of-VK2735)

> “Viking selected VK2735 from a series of internally developed dual GLP-1/GIP receptor agonists”

Source: [Viking Therapeutics VK2735 pipeline page](https://vikingtherapeutics.com/pipeline/vk2735/)

<a id="topic-2.1.2.1-2"></a>

###### Name: development code VK2735

> “today announced the initiation of a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.”

Source: [Viking Therapeutics phase 1 initiation release (2022)](https://ir.vikingtherapeutics.com/2022-01-10-Viking-Therapeutics-Announces-Initiation-of-Phase-1-Clinical-Trial-of-VK2735,-Companys-Lead-Dual-GLP-1-GIP-Receptor-Agonist)

<a id="topic-2.1.2.1-3"></a>

###### Nonproprietary name

No evidence found.

<a id="topic-2.1.2.1-4"></a>

###### Brand name: one brand name expected for both formulations

> “We're going to have the second injectable dual agonist. We're going to have the first GLP-1/GIP dual agonist oral. It's the same molecule, so you'd expect it to be the same brand name.”

Source: [Viking Therapeutics Morgan Stanley conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/744429-morgan-stanley-24th-annual-global-healthcare-conference/)

<a id="topic-2.1.2.1-5"></a>

###### Therapeutic class: dual GLP-1 and GIP receptor agonist

> “VK2735 is a dual agonist of the GLP-1 and GIP receptors that we are developing for the potential treatment for various metabolic disorders.”

Source: [Viking Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526046876/vktx-20251231.htm)

> “This study aimed to determine doses of VK2735, a novel glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide (GLP‐1/GIP) receptor dual agonist, that are effective for weight loss over 13 weeks of treatment.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.1-6"></a>

###### Chemical class: peptide with a half-life-extending side chain

> “The VK2735 peptide incorporates the activities of both incretins and contains a side chain that imparts an extended half‐life when administered as a subcutaneous injection.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.1-7"></a>

###### Chemical structure, molecular formula, and molecular weight

No evidence found.

Additional sources: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500); [ClinicalTrials.gov NCT07868835](https://clinicaltrials.gov/study/NCT07868835)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Subcutaneous formulation: vial and syringe, then autoinjector, in phase 3

> “Both the VANQUISH-1 and VANQUISH-2 studies were initiated using a vial and syringe for administration of VK2735. In the fourth quarter of 2025, we initiated a bioequivalence study to allow for the introduction of an autoinjector device, which may represent a more convenient method of administration for some people.”

Source: [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/)

> “In the Q1 of 2026, participants in both VANQUISH studies began transitioning to the auto-injector device.”

Source: [Viking Therapeutics first quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/555372-q1-2026/)

> “I think certainly with VANQUISH 1, everybody's now on an auto-injector. I think for VANQUISH 2, almost everybody is on the auto-injector.”

Source: [Viking Therapeutics second quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/657331-q2-2026/)

<a id="topic-2.1.2.2-2"></a>

###### Subcutaneous formulation: phase 3 dose strengths

> “Participants in each trial have been randomized to weekly doses of 7.5 mg, 12.5 mg, 17.5 mg, or placebo.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-2.1.2.2-3"></a>

###### Oral formulation: once-daily tablet and phase 3 dose strengths

> “In addition to its subcutaneous formulation, Viking is also advancing an oral tablet formulation of VK2735.”
> “Participants in each trial will be randomized to one of four treatment groups receiving once-daily VK2735 doses of 27.5 mg, 35 mg, 55 mg, or placebo.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-2.1.2.2-4"></a>

###### Subcutaneous and oral formulations: contracted finished-product formats

> “Secures Dedicated Fill/Finish Capacity for 100 Million Annual Autoinjector Supply and Additional 100 Million Annual Vial/Syringe Supply”
> “This includes dedicated manufacturing lines and an annual commitment to supply 100 million autoinjectors and an additional 100 million vial and syringe products for the subcutaneous formulation, as well as an annual capacity of over one billion oral VK2735 tablets.”

Source: [Viking Therapeutics CordenPharma agreement release (2025)](https://ir.vikingtherapeutics.com/2025-03-11-Viking-Therapeutics-Signs-Broad-Manufacturing-Agreement-With-CordenPharma-to-Support-Commercialization-of-VK2735)

<a id="topic-2.1.2.2-5"></a>

###### Commercial strengths, package configuration, and national drug code

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

Not applicable.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Development indication stated by the company

> “VK2735 is being developed in both subcutaneous and oral formulations for the potential treatment of various metabolic disorders such as obesity.”

Source: [Viking Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526046876/vktx-20251231.htm)

<a id="topic-2.1.2.5-2"></a>

###### Subcutaneous formulation: phase 3 populations

> “The VANQUISH-1 study is fully enrolled with approximately 4,500 adults who do not have type 2 diabetes and who have obesity (BMI ≥30 kg/m2) or are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. The VANQUISH-2 study is also fully enrolled with approximately 1,000 adults with type 2 diabetes who have obesity or are overweight.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

<a id="topic-2.1.2.5-3"></a>

###### Oral formulation: phase 3 populations

> “SUNRISE-1 will include obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) adults without type 2 diabetes who have at least one weight-related comorbidity. SUNRISE-2 will enroll adults with type 2 diabetes who are obese or overweight.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

<a id="topic-2.1.2.5-4"></a>

###### Proposed U.S. labeled indication

No evidence found.

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Dual agonist of the GLP-1 and GIP receptors

> “VK2735 is a wholly owned long-acting dual agonist of the glucagon like peptide-1, or GLP-1 receptor, and the glucose dependent insulinotropic polypeptide, or GIP receptor, in development for the potential treatment of obesity and other metabolic disorders.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-2.1.2.6.1-2"></a>

###### Receptor binding affinity and half-life extension

> “VK2735 binds with high affinity to both the GLP‐1 receptor (IC50: 188 nM) and GIP receptor (IC50: 325 nM) (unpublished data, Viking Therapeutics, Inc.).”
> “The VK2735 peptide incorporates the activities of both incretins and contains a side chain that imparts an extended half‐life when administered as a subcutaneous injection.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.6.1-3"></a>

###### Physiological rationale for combined GLP-1 and GIP receptor activation

> “Activation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce appetite, lower body weight, and improve insulin sensitivity in patients with type 2 diabetes, obesity, or both. Concomitant activation of glucose-dependent insulinotropic polypeptide (GIP) receptors may potentiate the satiety and insulin-sensitizing effects of GLP-1 receptor activation, leading to enhanced clinical benefits.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-2.1.2.6.1-4"></a>

###### Incretin hormone physiology

> “GLP-1 and GIP are gut hormones secreted from intestinal L cells and K cells, respectively. Together, these hormones account for most of the enhanced insulin secretion observed in healthy adults after a meal.”

Source: [Viking Therapeutics VK2735 pipeline page](https://vikingtherapeutics.com/pipeline/vk2735/)

<a id="topic-2.1.2.6.1-5"></a>

###### Selection of VK2735 from an internally developed dual agonist series

> “Viking selected VK2735 from a series of internally developed dual GLP-1/GIP receptor agonists evaluated as part of a program focused on the development of best-in-class therapies for metabolic diseases.”

Source: [Viking Therapeutics VK2735 pipeline page](https://vikingtherapeutics.com/pipeline/vk2735/)

<a id="topic-2.1.2.6.1-6"></a>

###### Subcutaneous formulation: peptide administered once weekly

> “VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

<a id="topic-2.1.2.6.1-7"></a>

###### Oral formulation: same peptide administered once daily as a tablet

> “VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily”

Source: [ClinicalTrials.gov NCT07868835](https://clinicaltrials.gov/study/NCT07868835)

<a id="topic-2.1.2.6.1-8"></a>

###### One molecule in both formulations

> “An important factor in this differentiation is the ability to use the same dual-acting GLP-1 and GIP coagonist molecule in both subcutaneous and oral formulations.”

Source: [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/)

<a id="topic-2.1.2.6.1-9"></a>

###### Peptide sequence, structure, and oral absorption technology

No evidence found.

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Preclinical pharmacology of the dual agonist series: diet-induced obese mice compared with semaglutide

> “Treatment with Viking dual agonists resulted in mean reductions in body weight of up to 27% relative to vehicle (p<0.0001), compared with a mean reduction of 18% among semaglutide-treated animals (p<0.0001 vs. semaglutide)”
> “Treatment with Viking dual agonists resulted in mean reductions in blood glucose of up to 23% relative to vehicle (p<0.0001), compared with a mean reduction of 7% among semaglutide-treated animals (p<0.0001 vs. semaglutide)”

Source: [Viking Therapeutics ObesityWeek 2021 preclinical release (2021)](https://ir.vikingtherapeutics.com/2021-11-01-Viking-Therapeutics-Presents-Preclinical-Data-on-Novel-Dual-GLP-1-GIP-Agonists-at-ObesityWeek-R-2021)

<a id="topic-2.1.2.6.2-2"></a>

###### Preclinical pharmacology of the dual agonist series: diet-induced obese mice compared with tirzepatide

> “Treatment with Viking dual agonists resulted in mean reductions in body weight of up to 28% (p<0.0001 vs. vehicle) and reductions in plasma glucose of up to 26% (p<0.0001 vs. vehicle). These effects were comparable to those observed among tirzepatide-treated animals (29% and 25% reductions, respectively, vs. vehicle)”
> “Treatment with Viking dual agonists resulted in mean reductions in liver triglycerides of up to 49% relative to vehicle (p=0.01), compared with a 19% mean reduction among tirzepatide-treated animals (p<0.05 vs. tirzepatide)”

Source: [Viking Therapeutics ObesityWeek 2021 preclinical release (2021)](https://ir.vikingtherapeutics.com/2021-11-01-Viking-Therapeutics-Presents-Preclinical-Data-on-Novel-Dual-GLP-1-GIP-Agonists-at-ObesityWeek-R-2021)

<a id="topic-2.1.2.6.2-3"></a>

###### Preclinical pharmacology: 8-week weight change in obese primates compared with tirzepatide

> “Significant, progressive body weight reduction observed over 8 weeks”
> “~40%+ improvement in weight loss vs. comparator at same doses”
> “Aligns with improved exposures at same dose levels”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-2.1.2.6.2-4"></a>

###### Subcutaneous formulation: liver fat after four weekly doses in the phase 1 multiple ascending dose study

> “Following 28 days of once-weekly treatment with VK2735, study results demonstrated reductions in liver fat content, both as compared to baseline and as compared to placebo. Subjects receiving VK2735 experienced reductions in liver fat ranging up to 47.2% from baseline.”
> “In the subgroup of study subjects with non-alcoholic fatty liver disease (NAFLD), defined as those with greater than 5% liver fat at baseline, the reductions in liver fat levels were more pronounced. For these subjects, reductions from baseline after four weekly doses ranged up to 49.7%, and placebo-adjusted reductions of up to 58.5% were reported.”

Source: [Viking Therapeutics ObesityWeek 2023 release (2023)](https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-Presents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023)

<a id="topic-2.1.2.6.2-5"></a>

###### Subcutaneous formulation: plasma lipids in the phase 1 multiple ascending dose study

> “Dose dependent reductions from baseline in these plasma lipid levels were observed across VK2735 treatment cohorts after four weekly doses. No meaningful changes in levels of high-density lipoprotein cholesterol (HDL-C) were observed following treatment with VK2735.”

Source: [Viking Therapeutics ObesityWeek 2023 release (2023)](https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-Presents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023)

<a id="topic-2.1.2.6.2-6"></a>

###### Subcutaneous formulation: glycemic status and lipids at week 13 in the phase 2 trial

> “Of the 74 participants who had prediabetes at baseline, 58 (78%) shifted to normoglycemic at Week 13 in the active treatment groups and none shifted from prediabetes to diabetes.”
> “Lipid markers generally declined over the 13‐week study in the active treatment group”
> “Only total cholesterol had a p value less than 0.05 versus placebo”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.6.2-7"></a>

###### Subcutaneous formulation: fasting glucose, HbA1c, and blood pressure at week 13 in the phase 2 trial

| Measure, change from baseline (LS mean (SE)) | Placebo | 2.5 mg | 5.0 mg | 10 mg | 15 mg |
| --- | --- | --- | --- | --- | --- |
| Glucose, mg/dL | “−0.37 (1.475)” | “−10.66 (1.439)” | “−10.23 (1.424)” | “−9.46 (1.424)” | “−10.85 (1.456)” |
| Hemoglobin A1c, % | “0.03 (0.041)” | “−0.29 (0.040)” | “−0.27 (0.040)” | “−0.27 (0.039)” | “−0.36 (0.040)” |
| Systolic blood pressure, mmHg | “−4.20 (1.993)” | “−6.87 (1.906)” | “−6.71 (1.931)” | “−7.04 (1.936)” | “−10.97 (2.000)” |
| Diastolic blood pressure, mmHg | “−1.68 (1.286)” | “−3.27 (1.229)” | “−4.34 (1.246)” | “−2.37 (1.247)” | “−5.16 (1.290)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.6.2-8"></a>

###### Subcutaneous formulation: weight loss persisting after the last dose in the phase 2 trial

> “>90% of weight reduction maintained 4 weeks post-final dose”

Source: [Alkhouri et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/Results-From-the-13-Week-VENTURE-Phase-2a-Study-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Obese-Patients.pdf)

<a id="topic-2.1.2.6.2-9"></a>

###### Subcutaneous formulation: maximal effect not reached in 13 weeks

> “Maximal therapeutic levels were likely not yet achieved in this limited duration study.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.6.2-10"></a>

###### Oral formulation: satiety and appetite in the phase 1 multiple ascending dose study

> “Majority of subjects dosed ≥40 mg reported reduced appetite/increased satiety, including all subjects in 100 mg cohort.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-2.1.2.6.2-11"></a>

###### Oral formulation: weight loss persisting after the last dose and with every-other-day dosing

> “Durable weight loss observed up to Day 57, 4 weeks after last dose of VK2735”
> “QD to QoD transition produces similar weight loss and trajectory; suggests reduced exposures may be effective in maintenance setting”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-2.1.2.6.2-12"></a>

###### Gastric emptying, energy intake, and body composition in humans

No evidence found.

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Subcutaneous formulation: half-life and time to maximum concentration after single doses

> “Following single subcutaneous doses, VK2735 demonstrated a half-life of approximately 170 to 250 hours, a Tmax (time to reach maximum plasma concentration) ranging from approximately 75 to 90 hours, and excellent therapeutic exposures.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-2.1.2.6.3-2"></a>

###### Subcutaneous formulation: phase 1 pharmacokinetic summary in the sponsor presentation

> “Tmax ~72 hours, gradual onset; T1/2 170 – 253 hours, amenable to weekly dosing”
> “Excellent exposures from weekly dosing suggests less frequent dosing a possibility”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-2.1.2.6.3-3"></a>

###### Subcutaneous formulation: predictability of pharmacokinetics in the phase 1 single ascending dose study

> “In the SAD portion of the study, VK2735 demonstrated promising safety and tolerability, as well as a predictable pharmacokinetic (PK) profile.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-2.1.2.6.3-4"></a>

###### Subcutaneous formulation: pharmacokinetic parameters at 5.0 mg weekly in the phase 2 trial

| Dose | Cmax (ng/mL) | AUC0-168 (ng*h/mL) | T1/2 (h) |
| --- | --- | --- | --- |
| VK2735 5.0 mg | “1,120” | “158,000” | “171” |

Source: [Alkhouri et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/Results-From-the-13-Week-VENTURE-Phase-2a-Study-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Obese-Patients.pdf)

<a id="topic-2.1.2.6.3-5"></a>

###### Subcutaneous formulation: plasma levels after the last dose and the rationale for monthly dosing

> “PK, exposure profile suggests monthly dosing may be feasible”

Source: [Alkhouri et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/Results-From-the-13-Week-VENTURE-Phase-2a-Study-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Obese-Patients.pdf)

> “An evaluation of plasma levels of VK2735 at various timepoints following the 13-week study was also conducted. The company believes the results support the feasibility of once-monthly dosing in the maintenance setting.”

Source: [Viking Therapeutics VK2735 pipeline page](https://vikingtherapeutics.com/pipeline/vk2735/)

<a id="topic-2.1.2.6.3-6"></a>

###### Subcutaneous formulation: half-life cited for every-other-week and monthly maintenance regimens

> “We designed this study so that the compound has a pretty long half-life. It's 8- 10 days or so half-life. If you think of a dosing regimen being preferably every four to five half-lives, it raised the possibility early on that maybe we could dose monthly and reduce the frequency of injections.”

Source: [Viking Therapeutics Jefferies conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/678533-jefferies-global-healthcare-conference-2026/)

> “This supports the company's view that VK2735's differentiated PK profile, with an extended half-life and excellent long-term exposures, may provide for greater flexibility in dosing compared with existing options.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-2.1.2.6.3-7"></a>

###### Subcutaneous formulation: preclinical pharmacokinetics compared with tirzepatide in primates

> “PK profile demonstrates higher Cmax, later Tmax, longer T1/2 vs. tirzepatide”
> “Differences lead to increased exposures over time”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-2.1.2.6.3-8"></a>

###### Oral formulation: plasma exposure in preclinical models

> “We developed an oral tablet formulation that demonstrated encouraging plasma exposures in model studies.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-2.1.2.6.3-9"></a>

###### Oral formulation: dose proportionality of exposure in the phase 1 multiple ascending dose study

> “Plasma exposures increase predictably through 100 mg dose level”
> “Figure 6. Oral exposures demonstrate linearity with increasing dose.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-2.1.2.6.3-10"></a>

###### Oral formulation: bioavailability, half-life, and food effect

No evidence found.

<a id="topic-2.1.2.6.3-11"></a>

###### Distribution, metabolism, and elimination pathways

No evidence found.

Additional sources: [Lian et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1002/oby.23938)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

###### Approved prescribing information, boxed warnings, contraindications, and REMS

Not applicable.

<a id="topic-2.1.2.7.1-2"></a>

###### Subcutaneous formulation: adverse event profile in the phase 2 trial

> “The AE profile of VK2735 was primarily gastrointestinal, with decreased reported frequency upon continued use.”
> “The most common study drug‐related TEAEs were nausea (64/175 participants [36.6%]), constipation (37/175 [21.1%]), and vomiting (22/175 [12.6%]).”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.7.1-3"></a>

###### Subcutaneous formulation: discontinuation and serious adverse events in the phase 2 trial

> “In total, 16 of 175 participants (9.1%) experienced at least one TEAE leading to withdrawal of the study drug. The most common TEAEs experienced by these participants were nausea (five participants), vomiting (four participants), diarrhea (two participants), and headache (two participants).”
> “A total of 8 of 175 participants (4.6%) experienced a total of 12 TESAEs.”
> “One participant in the 5.0 mg dose group experienced two drug‐related TESAEs, atrial fibrillation (possibly related) and dehydration (probably related), which led to study discontinuation.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.7.1-4"></a>

###### Subcutaneous formulation: adverse events of special interest and treatment discontinuation by dose in the phase 2 trial

| Event, n (%) | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
| --- | --- | --- | --- | --- | --- |
| TEAE leading to treatment discontinuation | “0” | “1 (3)” | “4 (11)” | “4 (11)” | “7 (20)” |
| Treatment-emergent serious adverse events | “1 (3)” | “2 (6)” | “2 (6)” | “2 (6)” | “1 (3)” |
| Pancreatitis | “0” | “0” | “0” | “0” | “0” |
| Gallbladder associated events | “0” | “1 (3)” | “0” | “0” | “1 (3)” |
| Injection site reactions | “3 (9)” | “2 (6)” | “5 (14)” | “5 (14)” | “4 (11)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.7.1-5"></a>

###### Subcutaneous formulation: gastrointestinal adverse events with a 5.0 mg starting dose

> “Nausea was highest in the first week in the 15 mg dose group; this group had a 5.0 mg starting dose, rather than the 2.5 mg starting dose in all other treatment groups”
> “GI AEs were generally observed early in the study and subsided over time”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.7.1-6"></a>

###### Subcutaneous formulation: heart rate change at week 13 in the phase 2 trial

| Heart rate, bpm | Placebo | 2.5 mg | 5.0 mg | 10 mg | 15 mg |
| --- | --- | --- | --- | --- | --- |
| Baseline, mean (SD) | “74.2 (11.01)” | “69.9 (10.46)” | “70.2 (10.45)” | “71.7 (8.53)” | “69.3 (9.94)” |
| Change from baseline, mean (SD) | “1.4 (12.15)” | “3.3 (11.94)” | “6.1 (9.33)” | “9.3 (8.51)” | “6.9 (8.43)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.7.1-7"></a>

###### Subcutaneous formulation: anti-drug antibodies in the phase 2 trial

> “At Week 13, anti‐drug antibodies were detected in between 9% (2.5 mg group) and 23% (10 mg group) of participants in any treatment group”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.7.1-8"></a>

###### Subcutaneous formulation: gallstone obstruction and hypoglycemia in the phase 1 multiple ascending dose study

> “One serious adverse event (SAE) was reported in a subject receiving VK2735. A subject with a history of cholelithiasis (gallstones) experienced an SAE of acute choledocholithiasis (gallstone obstruction).”
> “No subjects were discontinued for nausea, vomiting, or GI adverse events. Despite robust activation of the incretin receptor pathways, no hypoglycemia was reported.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-2.1.2.7.1-9"></a>

###### Subcutaneous formulation: tolerability with two-week titration steps and with every-other-week or monthly maintenance

> “One subject (1%) in the induction period discontinued VK2735 treatment due to an adverse event.”
> “Despite the accelerated 2-week titration schedule utilized in this study, rates of common GI adverse events such as nausea, vomiting, constipation, and diarrhea were similar to those reported in the prior Phase 2 study, which utilized 3-week titration steps.”
> “Rates of GI-related adverse events such as vomiting, nausea, diarrhea, and constipation were not meaningfully different from placebo over the 12-week maintenance window.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-2.1.2.7.1-10"></a>

###### Oral formulation: discontinuation and gastrointestinal adverse events in the phase 2 trial

> “During the study 13% of participants receiving placebo discontinued treatment due to an adverse event, compared with 20% of participants receiving VK2735 treatment. The most common reasons for treatment discontinuation were gastrointestinal (GI)-related adverse events. Overall treatment discontinuation rates were 18% among placebo subjects compared with 28% among VK2735 subjects.”
> “Nausea was reported among 58% of participants receiving VK2735 compared with 48% for placebo.”
> “Vomiting was reported in 26% of VK2735-treated subjects compared with 10% among subjects receiving placebo.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-2.1.2.7.1-11"></a>

###### Oral formulation: treatment discontinuation by dose in the phase 2 trial

> “Treatment discontinuations generally dose-dependent; may be related to titration rate”
> “Most common TEAEs leading to discontinuation of drug: nausea, vomiting, constipation”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-2.1.2.7.1-12"></a>

###### Oral formulation: serious and drug-related adverse events by cohort in the phase 1 multiple ascending dose study

| Event, number of subjects (%) | Placebo (n=19) | 2.5 mg (n=8) | 5 mg (n=7) | 10 mg (n=6) | 20 mg (n=8) | 40 mg (n=8) | 60 mg (n=9) | 80 mg A (n=9) | 80 mg B (n=9) | 100 mg (n=9) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Drug related TEAEs | “11 (58%)” | “4 (50%)” | “4 (57%)” | “3 (50%)” | “4 (50%)” | “7 (88%)” | “6 (67%)” | “9 (100%)” | “7 (78%)” | “9 (100%)” |
| Serious adverse events | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “1 (11%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” |

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-2.1.2.7.1-13"></a>

###### Oral formulation: company statement on serious adverse events in the phase 1 multiple ascending dose study

> “In addition, oral VK2735 demonstrated encouraging safety and tolerability following 28 days of once-daily dosing, and no serious adverse events (SAEs) have been reported to date.”

Source: [Viking Therapeutics VK2735 pipeline page](https://vikingtherapeutics.com/pipeline/vk2735/)

<a id="topic-2.1.2.7.1-14"></a>

###### Subcutaneous formulation: thyroid, pancreatitis, and calcitonin exclusion criteria in the phase 2 and phase 3 trials

> “Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)”
> “History of acute or chronic pancreatitis”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

> “Current or past diagnosis of chronic pancreatitis”
> “Calcitonin ≥20 ng/L measured by central laboratory at screening (individuals with elevated calcitonin at initial screening may be re-screened)”

Source: [ClinicalTrials.gov NCT06068946](https://clinicaltrials.gov/study/NCT06068946)

<a id="topic-2.1.2.7.1-15"></a>

###### Oral formulation: thyroid, pancreatitis, and calcitonin exclusion criteria in the phase 2 and phase 3 trials

> “Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)”
> “History of acute or chronic pancreatitis”

Source: [ClinicalTrials.gov NCT07868835](https://clinicaltrials.gov/study/NCT07868835)

> “Current or past diagnosis of chronic pancreatitis”
> “Calcitonin ≥50 ng/L measured by central laboratory at screening (individuals with elevated calcitonin at initial screening may be re-screened)”

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055)

<a id="topic-2.1.2.7.1-16"></a>

###### Class context: boxed warning for thyroid C-cell tumors in the tirzepatide (Zepbound) prescribing information

> “In rats, tirzepatide causes thyroid C-cell tumors. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined”
> “ZEPBOUND is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).”

Source: [Eli Lilly Zepbound prescribing information (2026)](https://uspl.lilly.com/zepbound/zepbound.html)

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Subcutaneous formulation: adults with type 2 diabetes in VANQUISH-2

> “Have Type 2 Diabetes Mellitus according to the American Diabetes Association with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening.”
> “Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening”
> “Have proliferative diabetic retinopathy OR diabetic macular edema OR non-proliferative diabetic retinopathy that requires acute treatment”

Source: [ClinicalTrials.gov NCT07104383](https://clinicaltrials.gov/study/NCT07104383)

<a id="topic-2.1.2.8-2"></a>

###### Oral formulation: adults with type 2 diabetes in SUNRISE-2

> “Have Type 2 Diabetes Mellitus according to the American Diabetes Association (See Section 12.5), with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening.”
> “Have non-proliferative diabetic retinopathy that requires acute treatment OR diabetic macular edema OR proliferative diabetic retinopathy identified during a dilated fundoscopy examination performed within 3 months of screening.”

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939)

<a id="topic-2.1.2.8-3"></a>

###### Subcutaneous formulation: adults with diabetes excluded from VANQUISH-1 and the phase 2 trial

> “Current or past diagnosis of diabetes mellitus (including type 1, type 2, except gestational diabetes)”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

> “Participants with BMI > 50 kg/m”
> “or with certain medical conditions, including diabetes, were not eligible.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.8-4"></a>

###### Oral formulation: adults with diabetes excluded from SUNRISE-1

> “Current or past diagnosis of diabetes mellitus (including type 1, type 2, except gestational diabetes). If a participant has had gestational diabetes, they are allowed to be enrolled as long as the glycemic status has returned to normal levels after 12 months of completion of pregnancy”

Source: [ClinicalTrials.gov NCT07868835](https://clinicaltrials.gov/study/NCT07868835)

<a id="topic-2.1.2.8-5"></a>

###### Pediatric participants: minimum age in the phase 3 trials

> “Age ≥18 years of age at the time of signing the informed consent”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

<a id="topic-2.1.2.8-6"></a>

###### Pediatric participants: clinical data with either formulation

No evidence found.

<a id="topic-2.1.2.8-7"></a>

###### Subcutaneous formulation: age range in the phase 1 study

> “Healthy volunteers, and otherwise healthy volunteers who have an increased body mass index, between the ages of 18 and 65 years.”

Source: [ISRCTN ISRCTN47896018](https://www.isrctn.com/ISRCTN47896018)

<a id="topic-2.1.2.8-8"></a>

###### Oral formulation: age of participants in the phase 2 trial

> “Mean age was 51 years for entire population, 83% of participants were <65 years”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-2.1.2.8-9"></a>

###### Renal impairment: exclusion criteria

> “Impaired renal function”

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf)

> “Impaired renal function with estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 as measured at Screening.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-2.1.2.8-10"></a>

###### Hepatic impairment: exclusion criterion in the maintenance study

> “Alanine aminotransferase (ALT) level or aspartate transaminase (AST) level > 3.0 times the ULN for the reference range.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-2.1.2.8-11"></a>

###### Renal or hepatic impairment: pharmacokinetic data with either formulation

No evidence found.

<a id="topic-2.1.2.8-12"></a>

###### Pregnancy and contraception: requirements in the phase 1 studies

> “Willing to comply with contraceptive requirements.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

> “Willing to comply with contraception requirements”

Source: [ClinicalTrials.gov NCT05203237](https://clinicaltrials.gov/study/NCT05203237)

<a id="topic-2.1.2.8-13"></a>

###### Pregnancy and lactation: clinical data with either formulation

No evidence found.

<a id="topic-2.1.2.8-14"></a>

###### Class context: pregnancy in the tirzepatide (Zepbound) prescribing information

> “Pregnancy: May cause fetal harm. When pregnancy is recognized, discontinue ZEPBOUND.”

Source: [Eli Lilly Zepbound prescribing information (2026)](https://uspl.lilly.com/zepbound/zepbound.html)

<a id="topic-2.1.2.8-15"></a>

###### Subcutaneous formulation: demographic enrollment goals in VANQUISH-1

> “Enrollment goals specified to achieve inclusive trial participation reflective of the real-world demographic”

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on VK2735

<a id="topic-2.1.2.9.1-1"></a>

###### Clinical drug interaction studies with either formulation

No evidence found.

<a id="topic-2.1.2.9.1-2"></a>

###### Metabolic pathway of VK2735

No evidence found.

<a id="topic-2.1.2.9.1-3"></a>

###### Oral formulation: effect of food or co-administered drugs on tablet absorption

No evidence found.

<a id="topic-2.1.2.9.1-4"></a>

###### Class context: metabolism of tirzepatide (Zepbound)

> “Tirzepatide is metabolized by proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid, and amide hydrolysis.”

Source: [Eli Lilly Zepbound prescribing information (2026)](https://uspl.lilly.com/zepbound/zepbound.html)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of VK2735 on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### Clinical drug interaction studies with either formulation

No evidence found.

<a id="topic-2.1.2.9.2-2"></a>

###### Effect of VK2735 on gastric emptying and absorption of oral medications

No evidence found.

<a id="topic-2.1.2.9.2-3"></a>

###### Class context: tirzepatide (Zepbound) with insulin or an insulin secretagogue

> “ZEPBOUND lowers blood glucose. When initiating ZEPBOUND, consider reducing the dose of concomitantly administered insulin or insulin secretagogues (e.g., sulfonylureas) to reduce the risk of hypoglycemia”

Source: [Eli Lilly Zepbound prescribing information (2026)](https://uspl.lilly.com/zepbound/zepbound.html)

<a id="topic-2.1.2.9.2-4"></a>

###### Class context: tirzepatide (Zepbound) with oral medications and oral hormonal contraceptives

> “ZEPBOUND delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with ZEPBOUND.”
> “Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation.”

Source: [Eli Lilly Zepbound prescribing information (2026)](https://uspl.lilly.com/zepbound/zepbound.html)

<a id="topic-2.1.2.9.2-5"></a>

###### Class context: tirzepatide (Zepbound) effects on CYP enzymes, transporters, and oral contraceptive exposure

> “In vitro studies have shown low potential for tirzepatide to inhibit or induce CYP enzymes, and to inhibit drug transporters.”
> “Following administration of a combined oral contraceptive (0.035 mg ethinyl estradiol and 0.25 mg norgestimate) in the presence of a single dose of tirzepatide 5 mg, mean C max of ethinyl estradiol, norgestimate, and norelgestromin was reduced by 59%, 66%, and 55%, while mean AUC was reduced by 20%, 21%, and 23%, respectively.”

Source: [Eli Lilly Zepbound prescribing information (2026)](https://uspl.lilly.com/zepbound/zepbound.html)

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Proposed labeled dose, titration, and dose modification

No evidence found.

<a id="topic-2.1.2.10.1-2"></a>

###### Subcutaneous formulation: maintenance doses in the VANQUISH phase 3 trials

> “Participants in each trial have been randomized to weekly doses of 7.5 mg, 12.5 mg, 17.5 mg, or placebo.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-2.1.2.10.1-3"></a>

###### Subcutaneous formulation: titration schedule in the VANQUISH phase 3 trials

> “What we did in the phase III is we've started people at 1.25 mgs for two weeks, then go up to 2.5 mgs for four, and you go up in 2.5 mg increments in four-week blocks.”

Source: [Viking Therapeutics Morgan Stanley conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/744429-morgan-stanley-24th-annual-global-healthcare-conference/)

> “So two weeks at 1.25 and then four weeks at 2.5, four weeks at 5, and so on up to 17.5. And when you get to 17.5, that's when the 52-week stable dose window starts.”

Source: [Viking Therapeutics J.P. Morgan conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/537697-44th-annual-j-p-morgan-healthcare-conference/)

<a id="topic-2.1.2.10.1-4"></a>

###### Subcutaneous formulation: rationale for the 1.25 mg starting dose

> “Given that the 5 mg dose had a higher GI TEAE rate than the 10 mg dose, there does not seem to be a dose‐dependent increase in GI TEAEs if a 2.5 mg starting dose is used at the beginning of the titration phase. The clear benefit of starting below 5.0 mg and titrating up has informed the phase 3 trial design to further improve tolerability.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

> “When we think about GI tolerability, a lot of that is tied to the initial exposures and then the overall exposure as well. What is the dose level? Which is one of the reasons we started at 1.25 mgs in the VANQUISH studies.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-2.1.2.10.1-5"></a>

###### Subcutaneous formulation: doses and titration in the phase 2 trial

> “Participants who met eligibility criteria were randomized to one of four VK2735 weekly subcutaneous injection treatment groups (2.5, 5.0, 10, or 15 mg) or the matched placebo injection group in a 1:1:1:1:1 ratio on day 1”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

> “2.5 mg cohort = 2.5 x 13 weeks”
> “5.0 mg cohort = 2.5 mg x 3 wks, 5 mg x 10 wks”
> “10.0 mg cohort = 2.5 mg x 3 wks, 5 mg x 3 wks, 7.5 mg x 3 wks, 10 mg x 4 wks”
> “15.0 mg cohort = 5 mg x 3 wks, 7.5 mg x 3 wks, 10 mg x 3 wks, 15 mg x 4 wks”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-2.1.2.10.1-6"></a>

###### Subcutaneous formulation: doses in the phase 1 single and multiple ascending dose study

> “Well tolerated up to 7.5 mg single doses”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “Subjects received escalating weekly doses of 1.5 mg, 3.0 mg, 5.0 mg, 5.0 mg.”
> “The company believes tolerability data from this study indicate that higher doses may be achieved with longer titration windows.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-2.1.2.10.1-7"></a>

###### Subcutaneous formulation: induction doses and two-week titration in the maintenance study

> “Starting in Week 3, VK2735 doses were escalated every two weeks until final doses of 15.0 mg, 17.5 mg, 20.0 mg, or 22.5 mg were achieved.”
> “Subjects treated with VK2735 were titrated to final doses as indicated: Week 1 = 1.25 mg; Week 2 = 2.5 mg; Week 3-4 = 5.0 mg; Week 5-6 = 7.5 mg; Week 7-8 = 10.0 mg; Week 9-10 = 12.5 mg; Week 11-12 = 15.0 mg; Week 13-14 = 17.5 mg; Week 15-16 = 20.0 mg; Week 17 = 22.5 mg.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-2.1.2.10.1-8"></a>

###### Subcutaneous formulation: every-other-week and monthly maintenance regimens

> “At Week 21 subjects were transitioned to maintenance dosing as indicated and treated for 12 weeks: 17.5 mg weekly to 5.0 mg QOW; 15 mg weekly to 7.5 mg QOW; 17.5 mg weekly to 10 mg QOW.”
> “During the maintenance dosing period, participants were randomized to a range of monthly (every four weeks) and every-other-week dosing regimens to evaluate the effect of less frequent dosing on weight maintenance.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-2.1.2.10.1-9"></a>

###### Subcutaneous formulation: less frequent regimens in the VANQUISH-1 extension

> “In addition, the VANQUISH-1 extension study will include certain less-frequent dosing regimens, including every-other-week and monthly administration.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-2.1.2.10.1-10"></a>

###### Subcutaneous induction followed by oral or subcutaneous maintenance

> “As in Part 1, all participants will receive initial weekly subcutaneous doses of VK2735 for 21 weeks. Following Week 21, participants will transition to a range of VK2735 maintenance dosing options including daily oral doses, monthly subcutaneous doses, every-other-week subcutaneous doses, or placebo.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-2.1.2.10.1-11"></a>

###### Oral formulation: doses in the SUNRISE phase 3 trials

> “Participants in both trials will be randomly assigned to one of four treatment groups receiving once-daily VK2735 doses of 27.5 mg, 35 mg, 55 mg, or placebo.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

<a id="topic-2.1.2.10.1-12"></a>

###### Oral formulation: doses and titration in the phase 2 trial

> “Titration scheme: 15 mg cohort = 15 mg x 13 weeks; 30 mg cohort = 30 mg x 13 wks; 60 mg cohort = 30 mg x 2 wks, 60 mg x 11 wks; 90 mg cohort = 30 mg x 2 wks, 60 mg x 2 wks, 90 mg x 9 wks; 120 mg cohort = 30 mg x 2 wks, 60 mg x 2 wks, 90 mg x 2 wks, 120 mg x 7 wks.”
> “Potential Future Dose Range ~20 mg to ~60 mg”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-2.1.2.10.1-13"></a>

###### Oral formulation: down-titration from 90 mg to 30 mg daily in the phase 2 maintenance cohort

> “In this treatment group, participants were rapidly titrated to 90 mg daily doses. After 4 weeks of daily dosing at 90 mg, participants were down-titrated to 30 mg daily doses and maintained at 30 mg daily for 7 weeks.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-2.1.2.10.1-14"></a>

###### Oral formulation: doses and titration in the phase 1 multiple ascending dose study

> “Subjects treated with VK2735 were titrated to final doses as: 2.5 mg cohort = 2.5 daily x 4 weeks; 5 mg cohort = 2.5mg daily x 1 wk, 5 mg daily x 3 wks; 10 mg cohort = 5 mg daily x 1 wk, 10 mg daily x 3 wks; 20 mg cohort = 15 mg daily x 1 wk, 20 mg daily x 3 wks; 40 mg cohort = 20 mg daily x 1 wk, 40 mg daily x 3 wks; 60 mg cohort = 40 mg daily x 1 wk, 60 mg daily x 3 wks; 80 mg A = 60 mg daily x 1 wk, 80 mg daily x 3 wks; 80 mg B = 60 mg daily x 1 wk, 80 mg daily x 1 wk, 80 mg QoD x 2 wks; 100 mg cohort = 80 mg daily x 1 wk, 100 mg daily x 3 wks.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Instructions for use, injection sites, and storage

No evidence found.

<a id="topic-2.1.2.10.2-2"></a>

###### Subcutaneous formulation: once-weekly subcutaneous injection in the phase 3 trials

> “Each study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of VK2735 administered by subcutaneous injection once weekly for 78 weeks.”

Source: [Viking Therapeutics VANQUISH initiation release (2025)](https://ir.vikingtherapeutics.com/2025-06-25-Viking-Therapeutics-Announces-Initiation-of-Phase-3-Obesity-Clinical-Program-with-GLP-1-GIP-Agonist-VK2735)

<a id="topic-2.1.2.10.2-3"></a>

###### Subcutaneous formulation: dosing without regard to fasting in the phase 2 trial

> “On study days with PK sample collection scheduled, participants were similarly asked to fast for no less than 6 h. Fasting was not otherwise required for dosing.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.10.2-4"></a>

###### Subcutaneous formulation: vial and syringe, then an autoinjector after a bioequivalence study

> “Both the VANQUISH-1 and VANQUISH-2 studies were initiated using a vial and syringe for administration of VK2735. In the fourth quarter of 2025, we initiated a bioequivalence study to allow for the introduction of an autoinjector device, which may represent a more convenient method of administration for some people. We are happy to report that this study was successfully completed, enabling the introduction of the autoinjector for all participants in the VANQUISH program.”

Source: [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/)

> “In the Q1 of 2026, participants in both VANQUISH studies began transitioning to the auto-injector device.”

Source: [Viking Therapeutics first quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/555372-q1-2026/)

<a id="topic-2.1.2.10.2-5"></a>

###### Subcutaneous formulation: autoinjector use and clinic visit frequency in the phase 3 trials

> “I think certainly with VANQUISH 1, everybody's now on an auto-injector. I think for VANQUISH 2, almost everybody is on the auto-injector.”
> “Your clinic visits drop from four per month to one per month.”

Source: [Viking Therapeutics second quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/657331-q2-2026/)

<a id="topic-2.1.2.10.2-6"></a>

###### Subcutaneous formulation: vial and syringe in the maintenance study

> “These are going to be a vial and syringe. The study's well underway now, so no, we're not going to introduce the autoinjector in the maintenance study.”

Source: [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/)

<a id="topic-2.1.2.10.2-7"></a>

###### Oral formulation: once-daily tablet in the phase 3 trials

> “Each study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of VK2735, with patients receiving once-daily oral VK2735 for 68 weeks.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

<a id="topic-2.1.2.10.2-8"></a>

###### Oral formulation: administration relative to food, water, and other oral medications

No evidence found.

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Commercial manufacturing and supply agreement

> “today announced that it has signed a broad, multi-year manufacturing agreement with CordenPharma, an industry-leading contract development and manufacturing organization (CDMO), covering both the active pharmaceutical ingredient (API) and final finished product supply for its VK2735 program for obesity.”
> “Under the terms of the agreement, Viking has secured dedicated capacity for the manufacture of, and a commitment to supply annually, multiple metric tons of VK2735 API.”
> “These API and final finished product capacities are further expandable at Viking's option.”
> “In exchange for dedicated API and fill/finish capacity, Viking will make prepayments totaling $150 million, to be paid over the period from 2025 to 2028. Prepayments will be credited against future orders.”

Source: [Viking Therapeutics CordenPharma agreement release (2025)](https://ir.vikingtherapeutics.com/2025-03-11-Viking-Therapeutics-Signs-Broad-Manufacturing-Agreement-With-CordenPharma-to-Support-Commercialization-of-VK2735)

<a id="topic-2.1.2.11-2"></a>

###### Commercial organization and launch preparation

> “today announced the appointment of Neil Aubuchon as chief commercial officer.”

Source: [Viking Therapeutics chief commercial officer appointment release (2026)](https://ir.vikingtherapeutics.com/2026-01-07-Viking-Therapeutics-Announces-Appointment-of-Neil-Aubuchon-as-Chief-Commercial-Officer)

> “But we have an SVP of commercial who has been involved in multiple obesity drug launches. We've got a VP of market access underneath him. We've got a VP of medical affairs. We have health economics and outcomes research.”
> “But we've added staff just in the last quarter or so in tech ops, in CMC, supply chain, in quality and compliance.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-2.1.2.11-3"></a>

###### Planned distribution channels: cash pay, direct-to-consumer, and direct-to-employer

> “Second is, as a smaller company, one of the challenges smaller companies have is access. 50% of the business now is in cash.”
> “They are creating what they call a direct-to-employer option, where they are treating this like a gym membership, where they are subsidizing let us say $100 or $150 a month to their employees, and the employees are paying the incremental, call it whatever, $150 a month out of pocket. In that model, patients can go to whatever product they want. There is no formulary.”
> “The other thing is that there are companies out there now that are doing direct-to-consumer engagement and marketing, frankly better than big pharma companies are doing. All of those companies want to work with us.”

Source: [Viking Therapeutics Morgan Stanley conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/744429-morgan-stanley-24th-annual-global-healthcare-conference/)

> “To be able to partner with direct-to-consumer companies, and we're talking to just about all of them now gives us a really good opportunity.”
> “Again, the great thing about this is that it's not through PBM, so there's no rebate wall that we have to worry about.”

Source: [Viking Therapeutics Jefferies conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/678533-jefferies-global-healthcare-conference-2026/)

<a id="topic-2.1.2.11-4"></a>

###### Medicare coverage: GLP-1 Bridge program

> “We are also seeing the Medicare GLP-1 Bridge program go extremely well. The uptake, at least early days, has been very positive. We would expect to have access to that.”

Source: [Viking Therapeutics Morgan Stanley conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/744429-morgan-stanley-24th-annual-global-healthcare-conference/)

> “Finally, Medicare is going to be covering these drugs as of July 1st.”
> “I think that that channel's going to be open to us as well.”

Source: [Viking Therapeutics Jefferies conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/678533-jefferies-global-healthcare-conference-2026/)

<a id="topic-2.1.2.11-5"></a>

###### Commercialization rights and partnering

> “Neil is a perfect fit to lead our commercialization strategy for VK2735, including engagement with potential strategic partners, representing a key step in our preparation for commercial success”

Source: [Viking Therapeutics chief commercial officer appointment release (2026)](https://ir.vikingtherapeutics.com/2026-01-07-Viking-Therapeutics-Announces-Appointment-of-Neil-Aubuchon-as-Chief-Commercial-Officer)

> “As far as partnering, there are a lot of different options available to us, and I think those companies, they provide a pretty good avenue to access the market, but probably not something that we're going to disclose at this point.”

Source: [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/)

> “First of all, we've stated publicly that we are always open to strategic collaborations, so whatever we do is not going to get in the way of that. But at the same time, we have to plan for the business as if we're running it ourself.”

Source: [Viking Therapeutics Morgan Stanley conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/744429-morgan-stanley-24th-annual-global-healthcare-conference/)

<a id="topic-2.1.2.11-6"></a>

###### Third-party payer reimbursement risk stated by the company

> “Although we believe that there will be a significant cash pay market for obesity drugs, there certainly would be a much larger obesity market with reimbursement from third-party payors and likely no viable commercial market for our other drug candidates, if approved, without reimbursement from third-party payors.”

Source: [Viking Therapeutics Form 10-Q third quarter (2026)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526436432/vktx-20260930.htm)

<a id="topic-2.1.2.11-7"></a>

###### Specialty pharmacy or distribution network

No evidence found.

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Subcutaneous formulation: reduced-calorie diet and exercise counseling in the phase 2 trial

> “All participants were encouraged to exercise for approximately 150 min per week and reduce daily intake by 500 kcal. Instructional materials were provided at Week 0 (i.e., randomization), and counseling sessions were conducted at study sites at Week 3, Week 6, and Week 9”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.12-2"></a>

###### Subcutaneous formulation: reduced-calorie diet and exercise counseling in the VANQUISH phase 3 trials

> “All groups: Counseling for reduced calorie diet and exercise”

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf); [Modesto et al. (2025c)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-2-Phase-3-Randomized-Double-blind-Placebo-controlled-Trial-of-weekly-subcutaneous-administration-of-VK2735-in-Obese-or-Overweight.pdf)

<a id="topic-2.1.2.12-3"></a>

###### Oral formulation: exercise and caloric intake advice in the phase 2 trial

> “All groups: Advised to exercise and reduce caloric intake”

Source: [Hedges et al. (2026)](https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf)

<a id="topic-2.1.2.12-4"></a>

###### Subcutaneous formulation: background glucose-lowering therapy permitted in VANQUISH-2

> “Type 2 diabetes mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists”

Source: [ClinicalTrials.gov NCT07104383](https://clinicaltrials.gov/study/NCT07104383)

<a id="topic-2.1.2.12-5"></a>

###### Oral formulation: background glucose-lowering therapy permitted in SUNRISE-2

> “Type 2 Diabetes Mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists.”

Source: [ClinicalTrials.gov NCT07868939](https://clinicaltrials.gov/study/NCT07868939)

<a id="topic-2.1.2.12-6"></a>

###### Subcutaneous formulation: glucose-lowering agents excluded in VANQUISH-1

> “Treatment with glucose-lowering agent(s) within 90 days before screening”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

<a id="topic-2.1.2.12-7"></a>

###### Subcutaneous formulation: prior incretin and weight-loss medications excluded

> “Use of any GLP-1 RA or dual GLP-1/GIP receptor agonist or analogs within 6 months of screening”

Source: [Modesto et al. (2025b)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/VANQUISH-1-Design-Phase-3-Trial-of-Subcutaneous-VK2735-in-Adults-with-Overweight-or-Obesity.pdf)

> “Any GLP-1 receptor agonist or GLP-1/GIP dual agonist within 6 months of Screening”
> “Any prescription or over-the-counter medications intended for weight loss within 6 months of screening”

Source: [ClinicalTrials.gov NCT06068946](https://clinicaltrials.gov/study/NCT06068946)

<a id="topic-2.1.2.12-8"></a>

###### Oral formulation: prior incretin and weight-loss medications excluded

> “Any GLP-1 receptor agonist or GLP-1/GIP dual agonist within 6 months of Screening”
> “Any prescription or over-the-counter medications intended for weight loss within 6 months of screening”

Source: [ClinicalTrials.gov NCT06828055](https://clinicaltrials.gov/study/NCT06828055)

<a id="topic-2.1.2.12-9"></a>

###### Subcutaneous formulation: prior or planned metabolic and bariatric surgery or endoscopic therapy excluded in VANQUISH-1

> “Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty if performed >1 year prior to screening)”
> “Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as, mucosa ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)”

Source: [ClinicalTrials.gov NCT07104500](https://clinicaltrials.gov/study/NCT07104500)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of VK2735 on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### Product-specific effect on quality measures

No evidence found.

<a id="topic-2.1.2.13-2"></a>

###### Merit-based Incentive Payment System 2026 measure 128: body mass index screening and follow-up plan

> “Percentage of patients aged 18 years and older with a BMI documented during the current encounter or within the previous twelve months AND who had a follow-up plan documented if the most recent BMI was outside of normal parameters.”
> “Proposed outline of treatment to be conducted as a result of a BMI outside of normal parameters.”
> “Pharmacological interventions”
> “This measure specification is only available for MIPS Value Pathway (MVP) reporting and is not available for traditional MIPS reporting.”

Source: [CMS Quality Payment Program measure 128 (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_128_MIPSCQM.pdf)

<a id="topic-2.1.2.13-3"></a>

###### Healthy People 2030 objective NWS-03: proportion of adults with obesity

| Field | Objective record |
| --- | --- |
| Objective | “Reduce the proportion of adults with obesity” |
| National baseline | “38.6” |
| National baseline definition | “percent of adults aged 20 years and over had obesity in 2013-16” |
| Most recent data | “40.2” |
| Most recent data period | “(2021-23)” |
| National target | “36.0” |
| National status | “Little or no detectable change” |
| Desired direction | “Decrease desired” |
| Data source | “National Health and Nutrition Examination Survey (NHANES), CDC/NCHS” |

Source: [ODPHP Healthy People 2030 NWS-03](https://odphp.health.gov/healthypeople/objectives-and-data/browse-objectives/overweight-and-obesity/reduce-proportion-adults-obesity-nws-03)

<a id="topic-2.1.2.13-4"></a>

###### Obesity quality measures in federal reporting and payment programs

> “Obesity quality measures have entered various stages of testing and development, but only a select few are included in reporting and payment programs.”
> “One process measure for adults, "Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan" is used in Medicare.”
> “No outcome or digital quality measure exists for the disease of obesity.”
> “The general absence of quality measures for obesity means that there are no objective measures to address the quality of obesity care or its outcome.”

Source: [Zvenyach and Pickering (2023)](https://pubmed.ncbi.nlm.nih.gov/37651080/)

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Semaglutide 2.4 mg subcutaneous: STEP 1 primary endpoint at week 68

> “In this double-blind trial, we enrolled 1961 adults with a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or greater (≥27 in persons with ≥1 weight-related coexisting condition), who did not have diabetes, and randomly assigned them, in a 2:1 ratio, to 68 weeks of treatment with once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo, plus lifestyle intervention.”
> “The mean change in body weight from baseline to week 68 was -14.9% in the semaglutide group as compared with -2.4% with placebo, for an estimated treatment difference of -12.4 percentage points (95% confidence interval [CI], -13.4 to -11.5; P<0.001).”
> “More participants in the semaglutide group than in the placebo group discontinued treatment owing to gastrointestinal events (59 [4.5%] vs. 5 [0.8%]).”

Source: [Wilding et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33567185/)

<a id="topic-2.1.2.14-2"></a>

###### Semaglutide 7.2 mg subcutaneous: STEP UP primary endpoint at week 72

> “Participants were randomly assigned (5:1:1) to receive once-weekly subcutaneous semaglutide 7·2 mg, 2·4 mg, or placebo, with a lifestyle intervention, for 72 weeks.”
> “The mean change in bodyweight was greater with semaglutide 7·2 mg versus 2·4 mg (-18·7% [SE 0·4] vs -15·6% [0·7]; estimated treatment difference [ETD] -3·1% [95% CI -4·7 to -1·6]; p<0·0001) and with semaglutide 7·2 mg versus placebo (-18·7% [0·4] vs -3·9% [0·6]; -14·8% [-16·2 to -13·4]; p<0·0001).”
> “Gastrointestinal adverse events were more common with semaglutide 7·2 mg (711 [70·8%] of 1004) versus 2·4 mg (123 [61·2%] of 201) or placebo (86 [42·8%] of 201), as was dysaesthesia (230 [22·9%], 12 [6·0%], and one [0·5%], respectively).”

Source: [Wharton et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/40961952/)

<a id="topic-2.1.2.14-3"></a>

###### Liraglutide 3.0 mg subcutaneous: SCALE Obesity and Prediabetes coprimary endpoints at week 56

> “We randomly assigned patients in a 2:1 ratio to receive once-daily subcutaneous injections of liraglutide at a dose of 3.0 mg (2487 patients) or placebo (1244 patients); both groups received counseling on lifestyle modification.”
> “At week 56, patients in the liraglutide group had lost a mean of 8.4±7.3 kg of body weight, and those in the placebo group had lost a mean of 2.8±6.5 kg (a difference of -5.6 kg; 95% confidence interval, -6.0 to -5.1; P<0.001, with last-observation-carried-forward imputation).”
> “A total of 63.2% of the patients in the liraglutide group as compared with 27.1% in the placebo group lost at least 5% of their body weight (P<0.001), and 33.1% and 10.6%, respectively, lost more than 10% of their body weight (P<0.001).”

Source: [Pi-Sunyer et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26132939/)

<a id="topic-2.1.2.14-4"></a>

###### Tirzepatide subcutaneous: SURMOUNT-1 primary endpoint at week 72

> “In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period.”
> “The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo).”
> “Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively.”

Source: [Jastreboff et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35658024/)

<a id="topic-2.1.2.14-5"></a>

###### Tirzepatide versus semaglutide subcutaneous: SURMOUNT-5 head-to-head primary endpoint at week 72

> “In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) subcutaneously once weekly for 72 weeks.”
> “A total of 751 participants underwent randomization. The least-squares mean percent change in weight at week 72 was -20.2% (95% confidence interval [CI], -21.4 to -19.1) with tirzepatide and -13.7% (95% CI, -14.9 to -12.6) with semaglutide (P<0.001).”

Source: [Aronne et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40353578/)

<a id="topic-2.1.2.14-6"></a>

###### Retatrutide subcutaneous, investigational: TRIUMPH-1 percent change in body weight at week 80

> “In this phase 3, randomized, double-blind trial, we assigned adults with obesity without diabetes to receive a once-weekly subcutaneous injection of retatrutide (at a dose of 4 mg, 9 mg, or 12 mg) or placebo for 80 weeks.”
> “A total of 2339 participants underwent randomization. The mean percent change in body weight in the retatrutide groups was -17.6% (4-mg dose), -23.7% (9-mg dose), and -25.0% (12-mg dose) versus -3.9% in the placebo group (differences, -19.8 and -21.0 percentage points, respectively; P<0.001 for both comparisons).”

Source: [Jastreboff et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42814954/)

<a id="topic-2.1.2.14-7"></a>

###### Cagrilintide-semaglutide subcutaneous, investigational: REDEFINE 1 coprimary endpoints at week 68

> “A total of 3417 participants underwent randomization, with 2108 assigned to receive cagrilintide-semaglutide, 302 to receive semaglutide, 302 to receive cagrilintide, and 705 to receive placebo.”
> “The estimated mean percent change in body weight from baseline to week 68 was -20.4% with cagrilintide-semaglutide as compared with -3.0% with placebo (estimated difference, -17.3 percentage points; 95% confidence interval, -18.1 to -16.6; P<0.001).”
> “Gastrointestinal adverse events (affecting 79.6% in the cagrilintide-semaglutide group and 39.9% in the placebo group), including nausea, vomiting, diarrhea, constipation, or abdominal pain, were mainly transient and mild-to-moderate in severity.”

Source: [Garvey et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40544433/)

<a id="topic-2.1.2.14-8"></a>

###### Semaglutide 2.4 mg subcutaneous in type 2 diabetes: STEP 2 primary endpoint at week 68

> “From June 4 to Nov 14, 2018, 1595 patients were screened, of whom 1210 were randomly assigned to semaglutide 2·4 mg (n=404), semaglutide 1·0 mg (n=403), or placebo (n=403) and included in the intention-to-treat analysis.”
> “Estimated change in mean bodyweight from baseline to week 68 was -9·6% (SE 0·4) with semaglutide 2·4 mg vs -3·4% (0·4) with placebo. Estimated treatment difference for semaglutide 2·4 mg versus placebo was -6·2 percentage points (95% CI -7·3 to -5·2; p<0·0001).”

Source: [Davies et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33667417/)

<a id="topic-2.1.2.14-9"></a>

###### Tirzepatide subcutaneous in type 2 diabetes: SURMOUNT-2 primary endpoint at week 72

> “Adults (aged ≥18 years) with a body-mass index (BMI) of 27 kg/m2 or higher and glycated haemoglobin (HbA1c) of 7-10% (53-86 mmol/mol) were randomly assigned (1:1:1), using a computer-generated random sequence via a validated interactive web-response system, to receive either once-weekly, subcutaneous tirzepatide (10 mg or 15 mg) or placebo for 72 weeks.”
> “Least-squares mean change in bodyweight at week 72 with tirzepatide 10 mg and 15 mg was -12·8% (SE 0·6) and -14·7% (0·5), respectively, and -3·2% (0·5) with placebo, resulting in estimated treatment differences versus placebo of -9·6% percentage points (95% CI -11·1 to -8·1) with tirzepatide 10 mg and -11·6% percentage points (-13·0 to -10·1) with tirzepatide 15 mg (all p<0·0001).”

Source: [Garvey et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37385275/)

<a id="topic-2.1.2.14-10"></a>

###### Semaglutide 2.4 mg subcutaneous: weight regain after treatment withdrawal in the STEP 1 extension

> “From week 0 to week 68, mean weight loss was 17.3% (SD: 9.3%) with semaglutide and 2.0% (SD: 6.1%) with placebo. Following treatment withdrawal, semaglutide and placebo participants regained 11.6 (SD: 7.7) and 1.9 (SD: 4.8) percentage points of lost weight, respectively, by week 120, resulting in net losses of 5.6% (SD: 8.9%) and 0.1% (SD: 5.8%), respectively, from week 0 to week 120.”
> “One year after withdrawal of once‐weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two‐thirds of their prior weight loss, with similar changes in cardiometabolic variables.”

Source: [Wilding et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252/)

<a id="topic-2.1.2.14-11"></a>

###### Tirzepatide subcutaneous: SURMOUNT-4 randomized withdrawal from week 36 to week 88

> “At week 36, a total of 670 participants were randomized (1:1) to continue receiving tirzepatide (n = 335) or switch to placebo (n = 335) for 52 weeks.”
> “The mean percent weight change from week 36 to week 88 was −5.5% with tirzepatide vs 14.0% with placebo (difference, −19.4% [95% CI, −21.2% to −17.7%]; P < .001).”
> “The overall mean weight reduction from week 0 to 88 was 25.3% for tirzepatide and 9.9% for placebo.”

Source: [Aronne et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10714284/)

<a id="topic-2.1.2.14-12"></a>

###### Tirzepatide subcutaneous: SURMOUNT-MAINTAIN continued, reduced, or withdrawn dosing to week 112

> “After completing the initial weight-loss period with once weekly subcutaneous tirzepatide at the MTD (10 mg or 15 mg), adults (aged ≥18 years) with a BMI of 30 kg/m2 and above or 27 kg/m2 and above with one or more weight-related comorbidity, and a history of at least one self-reported unsuccessful dietary effort to lose bodyweight were randomly assigned in a 3:3:2 ratio to continue tirzepatide MTD, reduce to tirzepatide 5 mg, or switch to placebo for an additional 52 weeks.”
> “The model-based estimate percent change in bodyweight from baseline to week 112 was -21·9% (95% CI -23·5 to -20·3) with MTD”
> “-16·6% (95% CI -18·0 to -15·1) with 5 mg tirzepatide (ETD -6·6 [95% CI -8·3 to -5·0]), versus -9·9% (95% CI -11·1 to -8·8) with placebo (p<0·0001 for all comparisons)”

Source: [Horn et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/42119587/)

<a id="topic-2.1.2.14-13"></a>

###### Oral semaglutide 25 mg: OASIS 4 primary endpoint at week 64

> “The participants were randomly assigned in a 2:1 ratio to receive oral semaglutide (25 mg) or placebo once daily, plus lifestyle interventions.”
> “A total of 205 participants were randomly assigned to receive oral semaglutide, and 102 to receive placebo. The estimated mean change in body weight from baseline to week 64 was -13.6% in the oral semaglutide group and -2.2% in the placebo group (estimated difference, -11.4 percentage points; 95% confidence interval, -13.9 to -9.0; P<0.001).”
> “Gastrointestinal adverse events were more common with oral semaglutide than with placebo (74.0% vs. 42.2%).”

Source: [Wharton et al. (2025c)](https://pubmed.ncbi.nlm.nih.gov/40934115/)

<a id="topic-2.1.2.14-14"></a>

###### Oral orforglipron: ATTAIN-1 primary endpoint at week 72

> “In this phase 3, multinational, randomized, double-blind trial, we examined the safety and efficacy of once-daily orforglipron at doses of 6 mg, 12 mg, or 36 mg, as compared with placebo (assigned in a 3:3:3:4 ratio) as an adjunct to healthy diet and physical activity for 72 weeks.”
> “A total of 3127 patients underwent randomization. The mean change in body weight from baseline to week 72 was -7.5% (95% confidence interval [CI], -8.2 to -6.8) with 6 mg of orforglipron, -8.4% (95% CI, -9.1 to -7.7) with 12 mg of orforglipron, and -11.2% (95% CI, -12.0 to -10.4) with 36 mg of orforglipron, as compared with -2.1% (95% CI, -2.8 to -1.4) with placebo (P<0.001 for all comparisons with placebo).”
> “Adverse events resulted in treatment discontinuation in 5.3 to 10.3% of the patients in the orforglipron groups and in 2.7% of those in the placebo group.”

Source: [Wharton et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40960239/)

<a id="topic-2.1.2.14-15"></a>

###### Oral orforglipron: ATTAIN-MAINTAIN switch from injectable incretin therapy at week 52

> “Here this double-blind, placebo-controlled trial randomized participants previously treated with tirzepatide (cohort 1: N = 205) or semaglutide (cohort 2: N = 171) during the SURMOUNT-5 study to orforglipron once daily or placebo.”
> “Cohort 1 participants who achieved body weight plateau maintained a model-based estimate (MBE) of 74.7% (s.e.m. 4.05) of body weight reduction with orforglipron compared with an MBE of 49.2% (s.e.m. 3.92) with placebo”
> “Cohort 2 participants who achieved body weight plateau maintained an MBE of 79.3% (s.e.m. 4.42) of body weight reduction with orforglipron compared with an MBE of 37.6% (s.e.m. 7.46) with placebo”
> “Trial limitations include the absence of a comparator arm involving continued use of injectable obesity-management medications and the trial’s 1-year duration.”

Source: [Aronne et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13375559/)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Definition: World Health Organization body mass index thresholds for adults

> “Obesity is a chronic disease affecting 1.1 billion people worldwide”
> “It is driven by complex interactions between environmental, social, biological and behavioural determinants.”
> “overweight is a BMI greater than or equal to 25; and obesity is a BMI greater than or equal to 30.”

Source: [WHO (2026)](https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight)

<a id="topic-2.2.1.1-2"></a>

###### Definition: obesity as a chronic, relapsing disease in the WHO guideline

> “Obesity is a chronic, relapsing disease affecting over 1 billion people worldwide, driving substantial morbidity, mortality, and economic burden.”

Source: [Celletti et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41324410/)

<a id="topic-2.2.1.1-3"></a>

###### Definition: clinical and preclinical obesity in the Lancet Diabetes and Endocrinology Commission

> “The Commission defines obesity as a condition characterised by excess adiposity, with or without abnormal distribution or function of adipose tissue, and with causes that are multifactorial and still incompletely understood.”
> “We define clinical obesity as a chronic, systemic illness characterised by alterations in the function of tissues, organs, the entire individual, or a combination thereof, due to excess adiposity.”
> “We define preclinical obesity as a state of excess adiposity with preserved function of other tissues and organs and a varying, but generally increased, risk of developing clinical obesity and several other non-communicable diseases (eg, type 2 diabetes, cardiovascular disease, certain types of cancer, and mental disorders).”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.1-4"></a>

###### Definition: adiposity-based chronic disease in the AACE algorithm

> “This 2025 algorithm for the medical care of adults with obesity underscores that ABCD is a complex, chronic disease that necessitates long-term treatment and care.”

Source: [Nadolsky et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40956256/)

<a id="topic-2.2.1.1-5"></a>

###### Etiology: multifactorial causes and positive energy balance

> “Genetic, environmental, psychological, nutritional, and metabolic factors can induce alterations of the biological mechanisms that maintain normal mass, distribution, and function of adipose tissue, thus contributing to obesity.”
> “The accrual of body fat occurs as a function of positive energy balance, whereby the rate of appearance of macronutrients exceeds that of disappearance.”
> “The global rise in the prevalence of obesity is driven by social and environmental factors, in particular easy access to energy-dense, heavily marketed, processed foods that are palatable and inexpensive.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.1-6"></a>

###### Etiology: heritability and monogenic forms

> “Evidence from studies of families, twins, and adopted children shows that at least 40–70% of the variation in body weight is explainable by genetic factors (heritability).”
> “Mutations in single genes, chromosomal regions, and copy number variants can cause severe obesity, pointing to biological pathways that regulate energy intake, energy expenditure, and body weight.”
> “In particular, disruption of genes in the leptin-melanocortin pathway alters eating behaviour by increasing hunger, decreasing satiety, activating food reward cues, and increasing the preference for dietary fat.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.1-7"></a>

###### Etiology: obesogenic environments and biological susceptibility

> “Obesity is a chronic disease resulting from complex interactions between environmental and psychosocial influences and biological susceptibility.”
> “The global health challenge of obesity is driven by increasingly obesogenic environments that limit access to healthy, affordable and sustainably produced foods; constrain opportunities for safe physical activity; and are shaped by market forces and inadequate legal and regulatory frameworks.”
> “Obesity is characterized by dysregulation of neurobiological and metabolic pathways involved in appetite, energy balance and adipose tissue function, with genetic variation influencing individual susceptibility.”

Source: [WHO (2026)](https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight)

<a id="topic-2.2.1.1-8"></a>

###### Etiology: diet and environmental exposures

> “Thus, habitual consumption of highly palatable and energy-dense diets predispose to excess weight gain irrespective of macronutrient content.”
> “Beyond diet, environmental factors ranging from socioeconomic status to chemical exposures to sedentary lifestyle can confer obesity risk.”

Source: [Schwartz et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5546881/)

<a id="topic-2.2.1.1-9"></a>

###### Etiology: health behaviors, stress, health conditions, and medications

> “Obesity is a complex and costly chronic disease influenced by many factors. These factors include health behaviors, stress, health conditions and medications, genes, and people's environment.”
> “Some health conditions may lead to excess weight gain, obesity, or insulin resistance. These conditions include Cushing syndrome, polycystic ovary syndrome, or underactive thyroid.”
> “Some medications may also cause weight gain by disrupting the brain's signals for hunger or through other mechanisms.”
> “In specific, rare, single-gene disorders, genes can directly cause obesity. Examples of these disorders are Bardet-Biedl syndrome and Prader-Willi syndrome.”

Source: [CDC Risk Factors for Obesity (2025)](https://www.cdc.gov/obesity/risk-factors/risk-factors.html)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Chronic weight management

<a id="topic-2.2.1.2.1-1"></a>

###### United States adults: incidence of obesity, 2001 to 2017

> “Among 13,888 adults followed for 115,797 PYs, the incidence of obesity in 2001–2017 was 28.1/1000 PYs (95% CI: 26.7, 29.7).”
> “Over the periods 2001–2005, 2005–2009, and 2009–2013, the incidence of obesity was stable, but in 2013–2017 the incidence increased by 18% compared to 2009–2013 [IRR: 1.18 (95% CI: 1.06, 1.30)].”

Source: [Nielsen et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10196588/)

<a id="topic-2.2.1.2.1-2"></a>

###### United States adults: incidence of obesity by race, age, education, and baseline weight status

> “Blacks had higher obesity incidence [47.9/1000 PYs (95% CI: 42.7, 53.1)] than Whites [26.2/1000 PYs (95% CI: 24.6, 27.9)].”
> “Across race, obesity incidence was highest in young adults (20–29 y) [34.1/1000 PYs (95% CI: 31.5, 36.7)] and declined with age [age 70+ y: 18.9/1000 PYs (95% CI: 16.6, 21.8)].”
> “Those with overweight had an obesity risk 7 times higher than those with normal weight [62.1/1000 PYs (95% CI: 58.8, 65.3) vs. 8.8/1000 PYs (95% CI: 8.1, 9.6)].”
> “Those with less than high-school education had higher obesity incidence than those with education beyond high-school [39.4/1000 PYs (95% CI: 34.4, 44.4) vs. 24.7/1000 PYs (95% CI: 23.1, 26.3)].”

Source: [Nielsen et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10196588/)

<a id="topic-2.2.1.2.1-3"></a>

###### Framingham Heart Study: short-term and long-term risk of developing obesity

> “Four-year rates of developing obesity ranged from 5% to 7% in women and 7% to 9% in men.”
> “The long-term risks for overweight or more or obesity exceeded 50% and 25%, respectively, indicating a large public health burden.”

Source: [Vasan et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16204159/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Chronic weight management

<a id="topic-2.2.1.2.2-1"></a>

###### United States adults: measured prevalence of obesity, August 2021 to August 2023

> “During August 2021–August 2023, the prevalence of obesity in adults was 40.3%, with no significant differences between men and women.”
> “The prevalence was 39.2% in men and 41.3% in women.”
> “The prevalence of obesity in adults ages 40–59 was 46.4%, which was higher than the prevalence in adults ages 20–39 (35.5%) and 60 and older (38.9%).”
> “The prevalence of obesity was lower in adults with a bachelor’s degree or more (31.6%) than in adults with less education”

Source: [Emmerich et al. (2024)](https://www.cdc.gov/nchs/products/databriefs/db508.htm)

<a id="topic-2.2.1.2.2-2"></a>

###### United States adults: measured prevalence of severe obesity, August 2021 to August 2023

> “The prevalence of severe obesity in adults was 9.4% during August 2021–August 2023, and was higher in adults ages 20–39 (9.5%) and 40–59 (12.0%) than in adults age 60 and older (6.6%)”
> “The prevalence of severe obesity in men (6.7%) was lower than in women (12.1%) overall and for each age group.”

Source: [Emmerich et al. (2024)](https://www.cdc.gov/nchs/products/databriefs/db508.htm)

<a id="topic-2.2.1.2.2-3"></a>

###### United States adults: trends in obesity and severe obesity, 2013 to 2023

> “From 2013–2014 through August 2021–August 2023, the age-adjusted prevalence of obesity in adults did not change significantly, while the age-adjusted prevalence of severe obesity increased from 7.7% to 9.7%”
> “In the United States, the prevalence of obesity in adults remains above the Healthy People 2030 goal of 36.0%”

Source: [Emmerich et al. (2024)](https://www.cdc.gov/nchs/products/databriefs/db508.htm)

<a id="topic-2.2.1.2.2-4"></a>

###### United States adults: overweight, obesity, and severe obesity combined

> “In August 2021–August 2023, the age-adjusted prevalence of U.S. adults age 20 and older with obesity was 40.3%, including 9.7% with severe obesity and another 31.7% who were overweight.”
> “Unadjusted estimates were 40.3% for obesity, 9.4% for severe obesity, and 32.1% for overweight.”

Source: [Fryar et al. (2026)](https://www.cdc.gov/nchs/data/hestat/hestat111.htm)

<a id="topic-2.2.1.2.2-5"></a>

###### United States states and territories: self-reported prevalence of obesity, 2025

> “These maps are based on self-reported weight and height from the Behavioral Risk Factor Surveillance System (BRFSS).”
> “In 2025, among U.S. states and territories with available data, all had an obesity prevalence higher than 25%, except the District of Columbia (24.2%).”
> “Overall, the Midwest (35.5%) and South (34.8%) had the highest prevalence of obesity, followed by the West (30.7%) and the Northeast (29.6%).”
> “21 states, Guam, and Puerto Rico had an obesity prevalence between 35% and less than 40%.”
> “No state or territory had an obesity prevalence of 40% or higher.”

Source: [CDC Adult Obesity Prevalence Maps (2026)](https://www.cdc.gov/obesity/data-and-statistics/adult-obesity-prevalence-maps.html)

<a id="topic-2.2.1.2.2-6"></a>

###### United States adults: projected prevalence of obesity and severe obesity in 2030

> “The findings from our approach suggest with high predictive accuracy that by 2030 nearly 1 in 2 adults will have obesity (48.9%; 95% confidence interval [CI], 47.7 to 50.1), and the prevalence will be higher than 50% in 29 states and not below 35% in any state.”
> “Nearly 1 in 4 adults is projected to have severe obesity by 2030 (24.2%; 95% CI, 22.9 to 25.5), and the prevalence will be higher than 25% in 25 states.”

Source: [Ward et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31851800/)

<a id="topic-2.2.1.2.2-7"></a>

###### United States adults: overweight and obesity in 2021 and forecast to 2050

> “In 2021, an estimated 15·1 million (95% UI 13·5–16·8) children and young adolescents (aged 5–14 years), 21·4 million (20·2–22·6) older adolescents (aged 15–24 years), and 172 million (169–174) adults (aged ≥25 years) had overweight or obesity in the USA.”
> “By 2050, the total number of children and adolescents with overweight and obesity will reach 43·1 million (37·2–47·4) and the total number of adults with overweight and obesity will reach 213 million (202–221).”
> “In 2050, in most states, a projected one in three adolescents (aged 15–24 years) and two in three adults (≥25 years) will have obesity.”

Source: [GBD 2021 US Obesity Forecasting Collaborators (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11694015/)

<a id="topic-2.2.1.2.2-8"></a>

###### Global adults: overweight and obesity in 2024

> “In 2024, 2.6 billion adults aged 18 years and older were overweight, including 940 million adults who were living with obesity”
> “Prevalence of overweight varied by region, from 32% in the WHO South-East Asia Region and the African Region to 68% in the Region of the Americas.”
> “About 16% of adults aged 18 years and older worldwide were living with obesity in 2024. The worldwide prevalence of obesity more than doubled between 1990 and 2024.”

Source: [WHO (2026)](https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight)

<a id="topic-2.2.1.2.2-9"></a>

###### Global adults: overweight and obesity in 2021 and forecast to 2050

> “In 2021, an estimated 1·00 billion (95% uncertainty interval [UI] 0·989–1·01) adult males and 1·11 billion (1·10–1·12) adult females had overweight and obesity.”
> “China had the largest population of adults with overweight and obesity (402 million [397–407] individuals), followed by India (180 million [167–194]) and the USA (172 million [169–174]).”
> “Assuming the continuation of historical trends, by 2050, we forecast that the total number of adults living with overweight and obesity will reach 3·80 billion (95% UI 3·39–4·04), over half of the likely global adult population at that time.”

Source: [GBD 2021 Adult BMI Collaborators (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11920007/)

<a id="topic-2.2.1.2.2-10"></a>

###### Global adults: number with obesity in 2022, pooled population-based data

> “The number of women and men with obesity in 2022 was 504 million (489–520) and 374 million (358–391), respectively, which was an increase of 377 million (360–393) and 307 million (290–324), respectively, from 1990.”
> “The countries with the largest absolute numbers of adults with obesity in 2022 were the USA, China, and India.”

Source: [NCD Risk Factor Collaboration (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7615769/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Natural history: a chronic, relapsing course requiring lifelong care

> “The guidelines recognize obesity as a chronic, relapsing disease requiring lifelong care and emphasize early diagnosis and integrated, person-centered approaches combining behavioral, medical, surgical, and other interventions alongside prevention and management of comorbidities.”

Source: [Celletti et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41324410/)

<a id="topic-2.2.1.3-2"></a>

###### Natural history: regain of lost weight

> “A lack of effective options for long-term weight reduction magnifies the enormity of this problem; individuals who successfully complete behavioral and dietary weight-loss programs eventually regain most of the lost weight.”
> “The latter process explains why weight lost through changes of diet and/or lifestyle tends to be regained over time, a major obstacle to effective obesity treatment.”

Source: [Schwartz et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5546881/)

<a id="topic-2.2.1.3-3"></a>

###### Natural history: defense of body weight after weight loss

> “The body responds to weight loss induced by hypocaloric diets through a robust defensive mechanism, which increases hunger and the desire to eat while decreasing energy expenditure.”
> “The equilibrium body weight is fiercely defended by the brain, regardless of whether this set point represents a so-called healthy weight or an excessive degree of body fat in people with overweight or obesity.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.3-4"></a>

###### Natural history: progression from preclinical to clinical obesity and end-organ damage

> “Clinical obesity can lead to severe end-organ damage, causing life-altering and potentially life-threatening complications (eg, heart attack, stroke, and renal failure).”
> “Preclinical obesity is defined as excess adiposity with preserved organ and tissue function, accompanied by an increased risk of progression to clinical obesity or other non-communicable diseases.”
> “The development of organ dysfunction and obesity complications, whether cardiometabolic or biomechanical, can arise at different levels of adiposity in different individuals.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.3-5"></a>

###### All-cause mortality by body mass index category: individual-participant data meta-analysis

> “The HR for obesity grade 1 (BMI 30·0–<35·0 kg/m2) was 1·45, 95% CI 1·41–1·48; the HR for obesity grade 2 (35·0–<40·0 kg/m2) was 1·94, 1·87–2·01; and the HR for obesity grade 3 (40·0–<60·0 kg/m2) was 2·76, 2·60–2·92.”
> “For BMI over 25·0 kg/m2, mortality increased approximately log-linearly with BMI; the HR per 5 kg/m2 units higher BMI was 1·39 (1·34–1·43) in Europe, 1·29 (1·26–1·32) in North America, 1·39 (1·34–1·44) in east Asia, and 1·31 (1·27–1·35) in Australia and New Zealand.”

Source: [Global BMI Mortality Collaboration (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4995441/)

<a id="topic-2.2.1.3-6"></a>

###### Life expectancy: population-based cohort in the United Kingdom

> “Compared with individuals of healthy weight (BMI 18·5–24·9 kg/m2), life expectancy from age 40 years was 4·2 years shorter in obese (BMI ≥30·0 kg/m2) men and 3·5 years shorter in obese women”
> “Most causes, including cancer, cardiovascular diseases, and respiratory diseases, had a J-shaped association with BMI, with lowest risk occurring in the range 21–25 kg/m2.”

Source: [Bhaskaran et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6249991/)

<a id="topic-2.2.1.3-7"></a>

###### Mortality by maximum body mass index over 24 years of weight history: Framingham Heart Study

> “Among 6197 participants (mean [SD] age at baseline, 62.79 [8.98] years; 55.5% female), 3478 (56.1%) died during the follow-up.”
> “A monotonic association was observed between maximum BMI and mortality, with increasing risks observed across obese I (BMI of 30 to <35; hazard ratio [HR], 1.27; 95% CI, 1.14-1.41) and obese II (BMI of 35 to <40; HR, 1.93; 95% CI, 1.68-2.20) categories.”

Source: [Xu et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6324399/)

<a id="topic-2.2.1.3-8"></a>

###### Global deaths attributable to high body mass index

> “High BMI accounted for 4.0 million (2.7- 5.3) deaths globally, nearly 40% of which occurred among non-obese.”
> “More than two-thirds of deaths related to high BMI were due to cardiovascular disease.”

Source: [GBD 2015 Obesity Collaborators (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5477817/)

> “In 2023, higher-than-optimal BMI caused an estimated 3.7 million deaths by increasing the number of deaths from diseases such as cardiovascular diseases, diabetes and cancers”

Source: [WHO (2026)](https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Energy homeostasis and the defended level of body fat

> “Growing evidence suggests that obesity is a disorder of the energy homeostasis system, rather than simply arising from the passive accumulation of excess weight.”
> “A major area of emphasis is the science of energy homeostasis, the biological process that maintains weight stability by actively matching energy intake to energy expenditure over time.”

Source: [Schwartz et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5546881/)

<a id="topic-2.2.1.4-2"></a>

###### Central nervous system regulation of appetite and adipocyte mass

> “The subcortical brain regions interact with higher cortical brain areas and hormonal signals (eg, leptin and gut hormones such as GLP-1) to regulate adipocyte mass.”
> “Dysregulation in these neural circuits can lead to an imbalance between energy intake and expenditure, promoting uncontrolled fat accumulation, weight gain, and the development of obesity.”
> “NTS neurons express receptors for multiple satiety peptides such as leptin, melanocortin, and GLP-1, and are key contributors to satiety control.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.4-3"></a>

###### Gut-derived incretin hormones: GLP-1 and GIP

> “GLP-1 is secreted by L-cell enteroendocrine cells in the small intestine and colon in response to intraluminal nutrients, in particular glucose and fat.”
> “GLP-1 further influences nutrient utilization, as do other incretin hormones, by promoting insulin secretion and inhibiting glucagon secretion.”
> “However, drug trials consistently demonstrate that GLP-1 receptor agonism results in significant weight loss.”
> “GIP, like GLP-1, is an incretin hormone though it has previously been shown to have a minimal effect on weight.”
> “However, combination GIP and GLP-1 agonism results in robust weight loss, potentially related to GIP’s unique alterations in adipose cell lipid cycling”

Source: [Busebee et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10843116/)

<a id="topic-2.2.1.4-4"></a>

###### Adipose tissue expansion, inflammation, and ectopic fat

> “Hence, the pathophysiology of obesity not only involves an increase in total body fat, with preferential distribution to the intra-abdominal compartment in the presence of insulin resistance, but also ectopic lipid accrual into non-adipose tissues, especially in the liver, skeletal muscle, and the pancreas.”
> “Storing excess energy in adipocytes is associated with ischaemia and hypoxia, apoptosis, fibrosis, and a decrease in capillary density.”
> “Consequently, obesity functions as a chronically inflamed state that originates from adipose tissue but also occurs systemically.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.4-5"></a>

###### Insulin resistance and cardiometabolic progression

> “However, a clear majority of people with obesity suffer varying degrees of insulin resistance.”
> “For someone with insulin resistance, the effects can be subclinical over much of their lifespan, but eventually give rise to clinical manifestations such as prediabetes, dyslipidaemia, hypertension, metabolic syndrome, and hepatic steatosis, contributing to the development of type 2 diabetes, cardiovascular disease, and metabolic dysfunction-associated steatotic liver disease (MASLD).”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.4-6"></a>

###### Mechanisms of organ dysfunction

> “Obesity can directly cause organ dysfunction via several pathophysiological mechanisms, including the physical effect of increased adipose tissue mass, the presence of ectopic fat within tissues and organs, metabolic effects, inflammatory mechanisms, and psychological consequences (figure 3).”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.4-7"></a>

###### Visceral adiposity and cardiovascular risk

> “There may be a 2- to 3-fold variation in the amount of VAT at any level of total or subcutaneous adiposity.”
> “Thus, high waist circumference (WC) even in individuals with normal weight may unmask higher CVD risk because WC is an indicator of abdominal body fat, which is associated with cardiometabolic disease and CVD and is predictive of mortality.”

Source: [Powell-Wiley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8493650/)

<a id="topic-2.2.1.4-8"></a>

###### Pathophysiological and behavioral phenotypes

> “Consequently, four actionable phenotypes were established: abnormal satiation (measured by calories ingested to experience postprandial fullness), abnormal postprandial satiety (duration of fullness and measured by GE), emotional eating behavior (measured by questionnaires) and abnormal resting energy expenditure (measured by indirect calorimetry).”
> “This obesity-phenotype based classification aims to match a treatment to the underlying pathophysiological abnormality seen in patients with obesity.”

Source: [Busebee et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10843116/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Body mass index categories for adults

| BMI category | BMI range (kg/m2) |
| --- | --- |
| Underweight | “Less than 18.5” |
| Healthy weight | “18.5 to less than 25” |
| Overweight | “25 to less than 30” |
| Class 1 obesity | “30 to less than 35” |
| Class 2 obesity | “35 to less than 40” |
| Class 3 obesity (severe obesity) | “40 or greater” |

Source: [CDC Adult BMI Categories (2024)](https://www.cdc.gov/bmi/adult-calculator/bmi-categories.html)

<a id="topic-2.2.1.5-2"></a>

###### Screening and confirmation of excess adiposity: ADA Standards of Care

> “8.2a Screen for overweight and obesity using BMI annually. To confirm excess adiposity, additional assessments of body fat using anthropometric assessments (e.g., waist-to-hip ratio) or direct measurements (e.g., dual-energy X-ray absorptiometry, bioelectrical impedance analysis) could be considered where available/feasible.”
> “It is recommended that excess adiposity be confirmed by either direct measurement of body fat, where available, or at least one anthropometric criterion (e.g., waist circumference, waist-to-hip ratio, or waist-to-height ratio) in addition to BMI, using validated methods and cutoff points appropriate to age, sex, and ethnicity and particularly in individuals with BMI 25–34.9 kg/m2 and in certain populations (South Asian individuals), as these measurements better reflect metabolic disease”
> “Thus, although BMI is not a perfect measure of adiposity, it remains an acceptable measure for use by clinicians who may not have the resources to obtain additional measures of adiposity on all individuals.”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/)

<a id="topic-2.2.1.5-3"></a>

###### Diagnosis of clinical obesity: Lancet Diabetes and Endocrinology Commission criteria

> “To mitigate risk of both overdiagnosis and underdiagnosis of obesity, excess adiposity should be confirmed by at least one other anthropometric criterion (eg, waist circumference) or by direct fat measurement when available. However, in people with substantially high BMI levels (ie, >40 kg/m2) excess adiposity can be pragmatically assumed.”
> “We recommend that BMI should be used only as a surrogate measure of health risk at a population level, for epidemiological studies, or for screening purposes, rather than as an individual measure of health.”
> “We defined 18 criteria for the diagnosis of clinical obesity in adults (range of consensus 90–100%; table 2), plus 13 criteria in children and adolescents (range of consensus 96–100%; table 2).”
> “A combination of an obesity phenotype with signs, symptoms, limitations of daily activities, or any combination of these.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.5-4"></a>

###### Complication-centric diagnosis: AACE algorithm

> “(3) diagnosis: anthropometric component, (4) diagnosis: clinical component”
> “Emphasis is placed on optimizing health rather than just weight reduction and achieving clinical goals other than a singular focus on body mass index (ie, complication-centric care).”

Source: [Nadolsky et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40956256/)

<a id="topic-2.2.1.5-5"></a>

###### Waist circumference as a vital sign

> “We argue that BMI alone is not sufficient to properly assess or manage the cardiometabolic risk associated with increased adiposity in adults”
> “We recommend that health professionals are trained to properly perform this simple measurement and consider it as an important ‘vital sign’ in clinical practice.”

Source: [Ross et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7027970/)

<a id="topic-2.2.1.5-6"></a>

###### Limitations of body mass index across populations

> “BMI does not measure body fat directly, nor does it provide information on body fat distribution”
> “Despite these limitations, BMI is a simple and inexpensive screening tool for conditions that may increase the risk of certain chronic diseases.”

Source: [Emmerich et al. (2024)](https://www.cdc.gov/nchs/products/databriefs/db508.htm)

> “In particular, research suggests that health risks may begin at a lower BMI among Asian people compared with other race and Hispanic-origin groups”
> “Additionally, research suggests that BMI overestimates adiposity (body fat) among Black people at a given BMI compared with others”

Source: [Fryar et al. (2026)](https://www.cdc.gov/nchs/data/hestat/hestat111.htm)

<a id="topic-2.2.1.5-7"></a>

###### Early identification and assessment of complications by health practitioners

> “Health practitioners need to: routinely assess weight status and identify overweight and obesity early; provide evidence-based counselling on healthy diet, physical activity, sleep and other healthy behaviours to all; assess obesity-related complications, comorbidities, hypertension, diabetes, disability, mental health and other NCD risk factors”

Source: [WHO (2026)](https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight)

Additional sources: [Busetto et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38969880/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Respiratory symptoms: sleep-disordered breathing, breathlessness, and wheezing

> “Upper airway obstruction caused directly by obesity results in development of sleep disordered breathing, which exists on a spectrum, from snoring with increased upper airways resistance, to obstructive sleep apnoea and obesity hypoventilation syndrome.”
> “The physical effects of increased intra-abdominal and central adiposity on diaphragmatic compliance and lung function can also contribute to breathlessness, especially during periods of increased oxygen requirements such as physical activity, or during respiratory infection (including COVID-19).”
> “Wheezing can exist as an isolated symptom or exacerbate pre-existing respiratory diseases such as asthma and COPD.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.6-2"></a>

###### Musculoskeletal symptoms: joint pain and restricted mobility

> “Osteoarthritis, particularly affecting large, weight-bearing joints such as the hips and knees, develops as a direct effect of increased body size on these joints.”
> “Osteoarthritis compounded by excess body weight is associated with discomfort and pain, restricting mobility, which in turn contributes to further weight gain.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.6-3"></a>

###### Cardiovascular symptoms: heart failure, atrial fibrillation, and raised blood pressure

> “Chronic fatigue, lower limb edema due to impaired diastolic dysfunction- Heart Failure with Preserved Ejection Fraction - HFpEF”
> “Evidence in the past several years shows relatively rapid and sizeable improvements in major heart failure symptoms with drug-induced and lifestyle-induced weight loss among people with heart failure with preserved ejection fraction.”
> “Obesity is also causally associated with atrial fibrillation, with preliminary evidence of reduced incident atrial fibrillation from large weight loss (eg, >10% of total body mass).”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.6-4"></a>

###### Metabolic signs: hyperglycemia and dyslipidemia

> “In line with such interactions, many people with obesity present with raised triglycerides, surrogate evidence of excess liver fat, and often with reduced HDL cholesterol and elevated blood glucose and HbA1c concentrations.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.6-5"></a>

###### Reproductive and urinary symptoms: menstrual disturbance, infertility, hypogonadism, and incontinence

> “The clinical symptoms of these disorders are menstruation disturbances (due to impaired ovulation), hirsutism, acne, and impaired fertility.”
> “In men, obesity is a cause of hypogonadotropic hypogonadism resulting in spermatogenesis disturbances and erectile dysfunction.”
> “Urinary incontinence is common in women with obesity and develops due to high intra-abdominal pressure combined with pelvic floor dysfunction.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.6-6"></a>

###### Neurological symptoms: headache, visual loss, and peripheral neuropathy

> “Idiopathic intracranial hypertension, which typically presents with progressive and severe headaches, visual loss due to papilloedema, or both, is a less common but serious consequence of obesity.”
> “Obesity can also contribute to the development of peripheral neuropathy, independent of glycaemic status.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.6-7"></a>

###### Lymphatic and skin signs: lymphoedema and intertrigo

> “Lymphoedema of the lower limbs is strongly associated with severe obesity, particularly in women, which develops due to mechanical compression of lymphatic vessels and reduced drainage, with feelings of pain, tightness, or both, resulting in decreased range of motion.”
> “Skin-on-skin rubbing and excessive moisture damage skin, causing inflammation and rash (eg, intertrigo), which predispose skin to fungal and bacterial infections.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.6-8"></a>

###### Functional symptoms: limitation of activities of daily living

> “Obesity often generates disability that restricts routine activities of daily living, including aspects of its management, such as physical activity, meal preparation, and access to care.”
> “Physical restrictions can limit mobility, balance, and range of motion, impairing self-care activities including personal hygiene, bathing, toileting, dressing, and skin or foot care.”
> “Risks of falls causing injury are higher, related to poor mobility and postural stability, especially in people with class 2 or 3 obesity.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.6-9"></a>

###### Psychological symptoms: depression and disordered eating

> “Obesity at baseline increased the risk of onset of depression at follow-up (unadjusted OR, 1.55; 95% confidence interval [CI], 1.22-1.98; P < .001).”
> “However, depression increased the odds for developing obesity (OR, 1.58; 95% CI, 1.33-1.87; P < .001).”

Source: [Luppino et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20194822/)

> “Eating disorders are common among people living with obesity, especially binge eating disorder and night eating syndrome.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.6-10"></a>

###### Social symptoms: weight stigma and discrimination

> “People with obesity commonly face a pervasive, resilient form of social stigma. They are often subject to discrimination in the workplace as well as in educational and healthcare settings.”
> “Research indicates that weight stigma can cause physical and psychological harm, and that affected individuals are less likely to receive adequate care.”

Source: [Rubino et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7154011/)

> “Weight discrimination is reported by 19–42% of adults with higher BMI, particularly women.”
> “Health-services professionals are a common source of weight bias, which can lead to avoidance or delay in people seeking advice from health-care professionals.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Incidence of 18 comorbidities: systematic review and meta-analysis

> “Statistically significant associations with obesity were found with the incidence of type II diabetes, all cancers except esophageal and prostate cancer, all cardiovascular diseases, asthma, gallbladder disease, osteoarthritis and chronic back pain.”
> “Obesity defined by BMI was also most strongly associated with the incidence of type II diabetes in females (12.41 (9.03–17.06)).”

Source: [Guh et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2667420/)

<a id="topic-2.2.1.7-2"></a>

###### Obesity-related multimorbidity: Finnish cohorts and UK Biobank

> “Obesity was associated with 21 non-overlapping cardiometabolic, digestive, respiratory, neurological, musculoskeletal, and infectious diseases after Bonferroni multiple testing adjustment and ignoring HRs of less than 1·50.”
> “Compared with healthy weight, the confounder-adjusted HR for obesity was 2·83 (95% CI 2·74–2·93; PAF 19·9% [95% CI 19·3–20·5]) for developing at least one obesity-related disease, 5·17 (4·84–5·53; 34·4% [33·2–35·5]) for two diseases, and 12·39 (9·26–16·58; 55·2% [50·9–57·5]) for complex multimorbidity.”
> “The proportion of participants of healthy weight with complex multimorbidity by age 75 years was observed by age 55 years in participants with obesity”

Source: [Kivimäki et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8938400/)

<a id="topic-2.2.1.7-3"></a>

###### Cardiovascular disease: heart failure and atrial fibrillation

> “In a study of 5881 Framingham Heart Study participants, HF incidence increased by 5% in men and 7% in women for every 1-unit BMI increase after adjustment for other risk factors, and the risk of HF increased across the entire spectrum of BMI.”
> “Recent work has also suggested that higher BMI is more strongly associated with the risk of HFpEF than with HFrEF.”
> “Several prospective epidemiological studies demonstrate that obesity is associated with higher risk of incident coronary artery disease (CAD).”
> “Overweight and obesity elevate the risk of AF through numerous mechanisms, including structural and electric remodeling, which contribute to development of the arrhythmogenic substrate”

Source: [Powell-Wiley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8493650/)

<a id="topic-2.2.1.7-4"></a>

###### Cancer: sites with sufficient evidence for excess body fatness

> “Furthermore, we identified an additional eight cancers for which there is now also sufficient evidence that the absence of body fatness lowers cancer risk, including cancers of the gastric cardia, liver, gallbladder, pancreas, ovary, and thyroid, as well as multiple myeloma and meningioma.”
> “There was a strong dose–response relationship, with relative risks of approximately 1.5 for overweight, 2.5 for class 1 obesity, 4.5 for class 2 obesity, and 7.1 for class 3 obesity.”

Source: [Lauby-Secretan et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6754861/)

> “Obesity is associated with increased risk for 13 types of cancer that account for more than 40% of cancer diagnoses annually.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.7-5"></a>

###### Knee osteoarthritis: meta-analysis of prospective studies

> “The results showed that overweight and obesity were significantly associated with higher knee OA risks of 2.45 (95% CI 1.88 to 3.20, p<0.001) and 4.55 (95% CI 2.90 to 7.13, p<0.001), respectively.”
> “The risk of knee OA increases by 35% (95% CI 1.18 to 1.53, p<0.001) with a 5 kg/m2 increase in BMI.”

Source: [Zheng and Chen (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4679914/)

<a id="topic-2.2.1.7-6"></a>

###### Sleep-disordered breathing: prevalence in United States adults

> “Obesity is a strong causal factor for sleep-disordered breathing, and because of the ongoing obesity epidemic, previous estimates of sleep-disordered breathing prevalence require updating.”
> “The current prevalence estimates of moderate to severe sleep-disordered breathing (apnea-hypopnea index, measured as events/hour, ≥15) are 10% (95% confidence interval (CI): 7, 12) among 30–49-year-old men; 17% (95% CI: 15, 21) among 50–70-year-old men; 3% (95% CI: 2, 4) among 30–49-year-old women; and 9% (95% CI: 7, 11) among 50–70 year-old women.”

Source: [Peppard et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3639722/)

<a id="topic-2.2.1.7-7"></a>

###### Liver and kidney disease: MASLD and obesity-related glomerulopathy

> “Deposition of ectopic fat in the liver among susceptible individuals can lead to the development of MASLD.”
> “Once MASLD progresses beyond steatosis to steatohepatitis with fibrosis, there is substantial risk of cirrhosis, liver failure, and hepatocellular carcinoma.”
> “The development of obesity-related glomerulopathy is well recognised and can lead to end-stage kidney disease.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.7-8"></a>

###### Type 2 diabetes: progressive beta-cell dysfunction

> “Individuals predisposed to glucotoxicity and lipotoxicity of β cells have a gradual decline in insulin secretion, which becomes insufficient for normal metabolism of glucose, proteins, and lipids.”
> “Higher levels of adiposity worsen insulin resistance, increasing β-cell demand, particularly when fat is deposited ectopically in the liver and muscle.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Chronic weight management

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Obesity and health-related quality of life: systematic review of reviews

> “We found that in all populations, obesity was associated with significantly lower generic and obesity‐specific HRQoL.”
> “in population data from six countries the relationship between BMI and SF‐36 PCS was dose‐dependent, with poorer physical HRQoL occurring in those with higher BMIs, whereas MCS scores were reduced only in those with Class III obesity.”
> “Improved HRQoL was evident after non‐surgical weight loss, but was not consistently demonstrated, even in randomized controlled trials.”

Source: [Kolotkin and Andersen (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5600094/)

<a id="topic-2.2.1.8.1-2"></a>

###### Obesity and health-related quality of life: updated systematic review of reviews

> “In total, eight SLRs and/or meta‐analyses published since 2017 were identified. The results consistently demonstrated a negative association between obesity and HRQoL, with some evidence suggesting poorer HRQoL in people with adverse metabolic profiles.”
> “Notably, no SLRs on anti‐obesity medications were identified, limiting conclusions on this emerging treatment area.”

Source: [Flølo et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12705258/)

<a id="topic-2.2.1.8.1-3"></a>

###### Patient-reported impacts of excess weight in qualitative interviews

> “Participants consistently reported that excess weight limited physical activity and comfort, energy/stamina and self‐confidence/self‐esteem. Impacts on emotional, social and sexual functioning, as well as productivity and overall health, were also reported.”

Source: [Kolotkin et al. (2017a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5599949/)

<a id="topic-2.2.1.8.1-4"></a>

###### SF-12 physical and mental component scores by BMI class in U.S. adults

> “Higher BMI was associated with significantly lower scores on both SF‐12 PCS and MCS (Table 3). The median PCS score was 55.86 for NW respondents, while respondents with OW, C1, C2 and C3 obesity had a median PCS score of 54.52, 52.83, 51.28, and 47.21, respectively (p < 0.001). The median MCS score for respondents who were NW, OW, C1, C2, and C3 obesity was 54.74, 54.96, 54.59, 54.20, and 52.41, respectively (p < 0.001) (Table 3).”
> “The proportion of respondents who reported an inability to work increased significantly (p < 0.001) with increasing BMI category (NW: 10.3%; OW: 11.2%; C1: 14.6%; C2: 17.8%; C3: 26.9%) (Table 3).”

Source: [MacEwan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10804324/)

<a id="topic-2.2.1.8.1-5"></a>

###### SF-36v2, work productivity, and patient activation by BMI class in the National Health and Wellness Survey

> “In the overall population of 69,742 adult respondents with BMI ≥18.5kg/m2, a lower proportion of older adults were classified as class 2/3 obesity than those <65y (Table 1)”
> “Overall, as BMI increased people had greater negative effects on HRQoL, felt less involved with and in control of their healthcare, and had greater work productivity and activity impairments. The largest declines were generally observed between class 2 and 3 obesity categories.”
> “People with T2DM and obesity tended to have greater declines in physical functioning and more work and activity impairments than people with obesity without T2DM.”

Source: [Rozjabek et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7306452/)

<a id="topic-2.2.1.8.1-6"></a>

###### Utility decrement per unit of BMI used in the ICER model

> “Based on a study examining the relationship between BMI and EQ-5D–measured quality of life, each one-unit increase in BMI was associated with a 0.006 reduction in utility, after adjusting for key obesity-related comorbidities.”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-2.2.1.8.1-7"></a>

###### Weight stigma, bias, and patient-reported experience of care

> “People living with obesity also face substantial social stigma from the disease, with discrimination in workplace, education, and health care settings resulting in high rates of depression and anxiety.”
> “Weight bias – the view that individuals are to blame for their weight – in the health care setting can negatively affect provider-patient interactions and lead to both physical and psychological harm, including discouraging people from seeking care, causing delays in diagnosis and treatment, and contributing to poorer health outcomes.”
> “They also described the stigma and bias associated with obesity, which can affect individuals’ mental health, self-esteem, and their willingness to engage with the health care system for treatment.”
> “Even with insurance coverage, the high cost of therapy also affects medication persistence, as some individuals were not able to afford to stay on the drugs long-term, which then led to regain of weight.”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-2.2.1.8.1-8"></a>

###### Change in physical functioning and weight-related quality of life with a GLP-1 receptor agonist

> “At Week 68, a greater proportion of participants treated with semaglutide 2.4 mg than with placebo reached meaningful within-person change (MWPC) thresholds for IWQOL-Lite-CT Physical Function scores in STEP 1 (51.8% vs. 28.3%; p < 0.0001) and STEP 2 (39.6% vs. 29.5%; p = 0.0083)”
> “Semaglutide 2.4 mg significantly improved physical functioning, with greater proportions of participants achieving MWPC compared with placebo, and showed beneficial effects on WRQOL and HRQOL beyond physical functioning.”

Source: [Rubino et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38698650/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Excess annual medical expenditures associated with obesity in U.S. adults

> “Over 30 units of BMI, each one-unit BMI increase was associated with an additional cost of $253 (95% CI $167-$347) per person. Among adults, obesity was associated with $1,861 (95% CI $1,656-$2,053) excess annual medical costs per person, accounting for $172.74 billion (95% CI $153.70-$190.61) of annual expenditures. Severe obesity was associated with excess costs of $3,097 (95% CI $2,777-$3,413) per adult.”
> “We estimated continuous BMI-related health care expenditures using data from the Medical Expenditure Panel Survey (MEPS) 2011–2016 for 175,726 respondents.”
> “Costs are reported in $US 2019.”

Source: [Ward et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7990296/)

<a id="topic-2.2.1.8.2-2"></a>

###### Causal estimate of medical costs due to obesity by payer and obesity class

> “Adults with obesity in the United States compared with those with normal weight experienced higher annual medical care costs by $2,505 or 100%, with costs increasing significantly with class of obesity, from 68.4% for class 1 to 233.6% for class 3. The effects of obesity raised costs in every category of care: inpatient, outpatient, and prescription drugs. Increases in medical expenditures due to obesity were higher for adults covered by public health insurance programs ($2,868) than for those having private health insurance ($2,058). In 2016, the aggregate medical cost due to obesity among adults in the United States was $260.6 billion.”
> “The expenditure estimates were obtained from 2-part models of instrumental variables in which the respondent’s body mass index (BMI) was instrumented using the BMI of their biological child.”

Source: [Cawley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10394178/)

<a id="topic-2.2.1.8.2-3"></a>

###### Annual health care expenditures by BMI class in U.S. national survey data

> “Healthcare expenditures, adjusted to the 2019 consumer price index, significantly increased with increasing BMI category (Table 2). The average total annual expenditures among respondents with C3 obesity were 60% higher than for NW respondents ($9212 vs. $5,236, respectively; p < 0.001). Also, the average annual prescription drug expenditures were more than double for respondents with C3 obesity compared to NW respondents ($2954 vs. $1,232, respectively; p < 0.001). Annual expenditures were driven largely by inpatient and pharmacy costs, which increased with increasing BMI (Table 2).”
> “Compared to NW respondents (1.71 days per 6 months), the respondents in all the other BMI categories missed significantly more days of work due to illness or injury (OW: 2.30; C1: 2.47; C2: 2.66, C3: 2.92 days per 6 months; p < 0.001).”

Source: [MacEwan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10804324/)

<a id="topic-2.2.1.8.2-4"></a>

###### Work loss and indirect costs to employers by BMI class

> “719,482 employees (normal weight: 106,631, overweight: 230,637, obesity class 1: 185,850, obesity class 2: 101,909, obesity class 3: 94,455) were included. Outcomes increased with each higher BMI category for the mean number of absence hours ([in order of BMI category]: 262, 273, 285, 290, 304) and percentage of employees with a claim (STD: 6.8%, 7.6%, 9.7%, 11.7%, 17.0%; LTD: 0.4%, 0.4%, 0.5%, 0.6%, 0.8%; WC: 2.7%, 2.8%, 3.4%, 3.6%, 3.5%). Estimated costs to the employer associated with absenteeism, STD, LTD, and WC were $1,036, $611, $38, and $95 higher per year (respectively) in the obesity class 3 cohort relative to the normal weight cohort.”

Source: [Shinde et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11229424/)

<a id="topic-2.2.1.8.2-5"></a>

###### Estimated reduction in health care spending with weight loss

> “Overall, adults with employer-sponsored insurance with a weight loss of 5% were estimated to spend a mean of $670 (95% CI, $654-$686) less on health care (8% less), and those with a weight loss of 25% spent an estimated mean of $2849 (95% CI, $2783-$2916) less on health care (34% less). Among adults with Medicare who had 1 or more comorbid conditions, a 5% weight loss was estimated to reduce spending by $1262 (95% CI, $1217-$1306) (7% less) and a 25% weight loss was estimated to reduce health care spending by a mean of $5442 (95% CI, $5254-$5629) (31% less).”

Source: [Thorpe and Joski (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11621981/)

<a id="topic-2.2.1.8.2-6"></a>

###### Global economic impact of overweight and obesity

> “The economic impact of OAO in 2019 is estimated at 2.19% of global gross domestic product (GDP) ranging on average from US$20 per capita in Africa to US$872 per capita in the Americas and from US$6 in low-income countries to US$1110 in HICs.”
> “If current trends continue, by 2060, the economic impacts from OAO are projected to rise to 3.29% of GDP globally.”

Source: [Okunogbe et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9494015/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Chronic weight management on Families

Not applicable.

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

Not applicable.

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Lifestyle and Behavioral Interventions

<a id="topic-2.2.2.1.1-1"></a>

###### USPSTF recommendation for intensive multicomponent behavioral interventions

> “The USPSTF recommends that clinicians offer or refer adults with a body mass index (BMI) of 30 or higher (calculated as weight in kilograms divided by height in meters squared) to intensive, multicomponent behavioral interventions.”
> “Effective intensive behavioral interventions were designed to help participants achieve or maintain a ≥5% weight loss through a combination of dietary changes and increased physical activity”
> “Most interventions lasted for 1 to 2 years, and the majority had ≥12 sessions in the first year”

Source: [US Preventive Services Task Force (2018)](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/obesity-in-adults-interventions)

<a id="topic-2.2.2.1.1-2"></a>

###### Magnitude of weight loss with behavior-based interventions

> “At 12 to 18 months, pooled results showed greater weight loss among intervention participants (−2.39 kg [−5.3 lb] [95% CI, −2.86 to −1.93]; 67 trials [n = 22,065]”
> “The mean absolute change in weight ranged from −0.5 kg (−1.1 lb) to −9.3 kg (−20.5 lb) among intervention groups and from 1.4 kg (3.1 lb) to −5.6 (−12.3 lb) among control groups.”
> “Pooling the trials (9 studies; n = 3140) showed a significant reduction in the risk of developing type 2 diabetes over 1 to 9 years (pooled risk ratio, 0.67 [95% CI, 0.51 to 0.89]”

Source: [US Preventive Services Task Force (2018)](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/obesity-in-adults-interventions)

<a id="topic-2.2.2.1.1-3"></a>

###### High-intensity comprehensive lifestyle intervention in the AHA/ACC/TOS guideline

> “Prescribe on-site, high-intensity (ie, ≥14 sessions in 6 mo) comprehensive weight loss interventions provided in individual or group sessions by a trained interventionist.”
> “In comprehensive lifestyle interventions, overweight/obese individuals typically are prescribed a diet designed to induce an energy deficit of ≥500 kcal/d. This deficit often is sought by prescribing 1200 to 1500 kcal/d for women and 1500 to 1800 kcal/d for men.”
> “produce average weight losses of up to 8 kg in 6 months of frequent (ie, initially weekly) on-site treatment provided by a trained interventionist”

Source: [Jensen et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5819889/)

<a id="topic-2.2.2.1.1-4"></a>

###### Nutrition, physical activity, and behavioral therapy in adults with type 2 diabetes

> “Nutrition, physical activity, and behavioral therapy are recommended for people with type 2 diabetes and overweight or obesity to achieve both weight and health outcome goals.”
> “Interventions including high frequency of counseling (≥16 sessions in 6 months) with focus on nutrition changes, physical activity, and behavioral strategies to achieve a 500–750 kcal/day energy deficit (irrespective of macronutrient composition) should be recommended for weight loss when available.”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/)

<a id="topic-2.2.2.1.1-5"></a>

###### Behavioral therapy combined with GLP-1 therapy in the WHO guideline

> “WHO recommends long-term GLP-1 therapies combined with intensive behavioral therapy to maximize and sustain benefits.”
> “Both recommendations were graded conditional”

Source: [Celletti et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41324410/)

<a id="topic-2.2.2.1.1-6"></a>

###### Durability of intensive lifestyle intervention in Look AHEAD

> “After the first year of the intervention, ILI participants lost a mean of 8.6% of initial weight, compared with 0.7% for participants randomly assigned to a usual care group (p<.001), referred to as Diabetes Support and Education (DSE).”
> “When the intervention ended, ILI participants had a mean loss of 6.0%, as measured from randomization, compared to 3.5% for DSE.”
> “Thirty-one percent of ILI and 23.9% of DSE participants gained ≥2% (p<0.001) of EOI weight, while 36.3% and 45.9% of the two groups, respectively, lost ≥2% of EOI weight (p=0.001).”

Source: [Chao et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7437140/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 GLP-1 Receptor Agonists

<a id="topic-2.2.2.1.2-1"></a>

###### Semaglutide injection and tablets: FDA-approved indications

> “WEGOVY® injection is indicated in combination with a reduced calorie diet and increased physical activity:”
> “To reduce excess body weight and maintain weight reduction long term in:”
> “Adults with overweight in the presence of at least one weight-related comorbid condition.”
> “WEGOVY® tablets are indicated in combination with a reduced calorie diet and increased physical activity:”
> “Concomitant use of WEGOVY® (semaglutide) tablets or WEGOVY® (semaglutide) injection with other semaglutide- containing products or with any other GLP-1 receptor agonist is not recommended.”

Source: [Novo Nordisk Wegovy prescribing information (2026)](https://www.novo-pi.com/wegovy.pdf)

<a id="topic-2.2.2.1.2-2"></a>

###### Semaglutide injection: dosage escalation and maintenance dosages for weight reduction, including 7.2 mg

> “The recommended starting dosage of WEGOVY® injection is 0.25 mg administered subcutaneously once weekly.”
> “The maintenance dosage of WEGOVY® for weight reduction in adults is either 1.7 mg or 2.4 mg (recommended) injected subcutaneously once weekly.”
> “For patients who tolerate the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated, the dosage may be increased to a maximum dosage of 7.2 mg subcutaneously once weekly.”

Source: [Novo Nordisk Wegovy prescribing information (2026)](https://www.novo-pi.com/wegovy.pdf)

<a id="topic-2.2.2.1.2-3"></a>

###### Semaglutide tablets: administration on an empty stomach and maintenance dosage

> “Take one WEGOVY® tablet orally once daily on an empty stomach in the morning with water (up to 4 ounces).”
> “After taking a WEGOVY® tablet, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications”
> “The recommended maintenance dosage of WEGOVY® tablets is 25 mg orally once daily.”
> “If patients do not tolerate the 25 mg once daily maintenance dosage, consider switching to WEGOVY® injection 1.7 mg once weekly”

Source: [Novo Nordisk Wegovy prescribing information (2026)](https://www.novo-pi.com/wegovy.pdf)

<a id="topic-2.2.2.1.2-4"></a>

###### Semaglutide injection and tablets: boxed warning for thyroid C-cell tumors

> “In rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures.”
> “WEGOVY® is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).”

Source: [Novo Nordisk Wegovy prescribing information (2026)](https://www.novo-pi.com/wegovy.pdf)

<a id="topic-2.2.2.1.2-5"></a>

###### Semaglutide tablets: FDA approval for weight management in December 2025

> “PLAINSBORO, N.J., Dec. 22, 2025 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved once-daily Wegovy® pill, the first oral GLP-1 medicine for obesity in the US.”
> “1.5 mg starting dose available in early January for $149 per month with savings offers”

Source: [Novo Nordisk Wegovy pill approval announcement (2025)](https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-302648344.html)

<a id="topic-2.2.2.1.2-6"></a>

###### Semaglutide 2.4 mg subcutaneous: cardiovascular outcomes in participants without diabetes in SELECT

> “A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo.”
> “A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001).”
> “Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001).”

Source: [Lincoff et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37952131/)

<a id="topic-2.2.2.1.2-7"></a>

###### Semaglutide 2.4 mg subcutaneous: two-year weight change in STEP 5

> “The mean change in body weight from baseline to week 104 was −15.2% in the semaglutide group (n = 152) versus −2.6% with placebo (n = 152), for an estimated treatment difference of −12.6 %-points (95% confidence interval, −15.3 to −9.8; P < 0.0001).”
> “Gastrointestinal adverse events, mostly mild-to-moderate, were reported more often with semaglutide than with placebo (82.2% versus 53.9%).”

Source: [Garvey et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9556320/)

<a id="topic-2.2.2.1.2-8"></a>

###### American Gastroenterological Association 2022 guideline: recommendations for semaglutide 2.4 mg and liraglutide 3.0 mg

> “The panel strongly recommended the use of pharmacotherapy in addition to lifestyle intervention in adults with overweight and obesity (body mass index ≥30 kg/m2, or ≥27 kg/m2 with weight-related complications) who have an inadequate response to lifestyle interventions.”
> “The panel suggested the use of semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate ER, and naltrexone-bupropion ER (based on moderate certainty evidence), and phentermine and diethylpropion (based on low certainty evidence), for long-term management of overweight and obesity.”

Source: [Grunvald et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36273831/)

<a id="topic-2.2.2.1.2-9"></a>

###### American Diabetes Association 2026 Standards of Care: preferred incretin pharmacotherapy and continuation

> “In people with diabetes and overweight or obesity, the preferred pharmacotherapy should be a glucagon-like peptide 1 receptor agonist or dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist with greater weight loss efficacy (i.e., semaglutide or tirzepatide), especially considering their added weight-independent benefits.”
> “Obesity pharmacotherapy indicated for chronic therapy should be continued beyond reaching weight loss goals to maintain the health benefits, as discontinuation often results in recurrence of weight gain and worsening or reemergence of cardiometabolic risk factors.”
> “Clinical trials have shown that sudden discontinuation of semaglutide and tirzepatide results in weight recurrence of one-half to two-thirds of the weight loss within 1 year with reversal of cardiometabolic improvements”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/)

<a id="topic-2.2.2.1.2-10"></a>

###### World Health Organization 2025 guideline: conditional recommendation for long-term GLP-1 therapies

> “WHO recommends long-term GLP-1 therapies combined with intensive behavioral therapy to maximize and sustain benefits.”
> “Both recommendations were graded conditional, reflecting that GLP-1 therapies-with or without behavioral therapy-are effective, but limited long-term data, cost, system readiness, equity, variability in patient priorities, and context-specific feasibility remain considerations.”

Source: [Celletti et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41324410/)

<a id="topic-2.2.2.1.2-11"></a>

###### Semaglutide injection and tablets: wholesale acquisition cost

| Product and package | Quoted WAC price |
| --- | --- |
| Tablets, 25 mg, 30 tablets per bottle | “$1,349.02” |
| Injection, 2.4 mg dose, 4-pen package | “$1,349.02” |
| Wegovy HD injection, 7.2 mg dose, 4-pen package | “$1,349.02” |

Source: [Novo Nordisk Wegovy pricing information (2026)](https://www.novopricing.com/wegovy.html)

<a id="topic-2.2.2.1.2-12"></a>

###### Semaglutide injection and tablets: list price reduction effective January 2027

> “New, lower list price of $675 per month across Wegovy®, Ozempic®, and Rybelsus®, effective January 1, 2027, addresses access barriers to our innovative medicines, especially for patients whose out-of-pocket costs are linked to list price”
> “These changes in list price do not have an impact on direct-to-patient, self-pay prices”

Source: [Novo Nordisk list price reduction announcement (2026)](https://www.novonordisk-us.com/media/press-releases/novo-nordisk-lowers-wegovy-ozempic-list-price.html)

<a id="topic-2.2.2.1.2-13"></a>

###### Liraglutide and semaglutide: average wholesale price and National Average Drug Acquisition Cost

| Medication | Typical adult maintenance dose | AWP for 30-day supply | NADAC for 30-day supply |
| --- | --- | --- | --- |
| Liraglutide | “3 mg daily” | “$1,619” | “$1,303” |
| Semaglutide | “2.4 mg once weekly” | “$1,619” | “$1,302” |

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/)

Additional sources: [Gilbert et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40539956/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Dual GIP and GLP-1 Receptor Agonists

<a id="topic-2.2.2.1.3-1"></a>

###### Tirzepatide: FDA-approved indications

> “ZEPBOUND® is indicated in combination with a reduced-calorie diet and increased physical activity:”
> “to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.”
> “to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.”
> “Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”

Source: [Eli Lilly Zepbound prescribing information (2026)](https://uspl.lilly.com/zepbound/zepbound.html)

<a id="topic-2.2.2.1.3-2"></a>

###### Tirzepatide: dosage escalation and maintenance dosages

> “The recommended starting dosage of ZEPBOUND for all indications is 2.5 mg injected subcutaneously once weekly for 4 weeks.”
> “After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly. The dosage may be increased in 2.5 mg increments, after at least 4 weeks on the current dose”
> “The recommended maintenance dosage is 5 mg, 10 mg, or 15 mg, injected subcutaneously once weekly.”
> “The maximum dosage of ZEPBOUND for all indications is 15 mg injected subcutaneously once weekly.”

Source: [Eli Lilly Zepbound prescribing information (2026)](https://uspl.lilly.com/zepbound/zepbound.html)

<a id="topic-2.2.2.1.3-3"></a>

###### Tirzepatide: three-year weight change and progression to type 2 diabetes in participants with prediabetes

> “At 176 weeks, the mean percent change in body weight among the participants who received tirzepatide was -12.3% with the 5-mg dose, -18.7% with the 10-mg dose, and -19.7% with the 15-mg dose, as compared with -1.3% among those who received placebo (P<0.001 for all comparisons with placebo).”
> “Fewer participants received a diagnosis of type 2 diabetes in the tirzepatide groups than in the placebo group (1.3% vs. 13.3%; hazard ratio, 0.07; 95% confidence interval [CI], 0.0 to 0.1; P<0.001).”

Source: [Jastreboff et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39536238/)

<a id="topic-2.2.2.1.3-4"></a>

###### Tirzepatide: apnea-hypopnea index in moderate-to-severe obstructive sleep apnea in SURMOUNT-OSA

> “In trial 1, the mean change in AHI at week 52 was −25.3 events per hour (95% confidence interval [CI], −29.3 to −21.2) with tirzepatide and −5.3 events per hour (95% CI, −9.4 to −1.1) with placebo, for an estimated treatment difference of −20.0 events per hour (95% CI, −25.8 to −14.2) (P<0.001).”
> “In trial 2, the mean change in AHI at week 52 was −29.3 events per hour (95% CI, −33.2 to −25.4) with tirzepatide and −5.5 events per hour (95% CI, −9.9 to −1.2) with placebo, for an estimated treatment difference of −23.8 events per hour (95% CI, −29.6 to −17.9) (P<0.001).”

Source: [Malhotra et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11598664/)

<a id="topic-2.2.2.1.3-5"></a>

###### Tirzepatide: oral hormonal contraceptive counseling in the American Diabetes Association 2026 Standards of Care

> “Tirzepatide in particular may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying, an effect that is largest after the first dose and diminishes over time.”
> “Individuals using oral hormonal contraceptives should switch to a nonoral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation.”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/)

<a id="topic-2.2.2.1.3-6"></a>

###### Tirzepatide: self-pay price for the KwikPen and single-dose vial

> “Zepbound patients can access all doses in either multi-dose KwikPen or single-dose vial at the same self-pay price, starting at $299, available by prescription now through LillyDirect”
> “INDIANAPOLIS, Feb. 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound® (tirzepatide) to include the four-dose single-patient use KwikPen® that delivers a full month of treatment in one device.”
> “The price of Zepbound is the same for both KwikPen and single-dose vials with Zepbound Self Pay Journey Program.”

Source: [Eli Lilly Zepbound KwikPen announcement (2026)](https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-most-prescribed-weight-management)

<a id="topic-2.2.2.1.3-7"></a>

###### Tirzepatide: average wholesale price and National Average Drug Acquisition Cost

| Medication | Typical adult maintenance dose | AWP for 30-day supply | NADAC for 30-day supply |
| --- | --- | --- | --- |
| Tirzepatide | “5, 10, or 15 mg once weekly” | “$1,304” | “$1,022” |

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/)

Additional sources: [Eli Lilly Zepbound pricing information (2026)](https://www.lillypricinginfo.com/zepbound); [Eli Lilly Zepbound coverage and savings (2026)](https://zepbound.lilly.com/hcp/coverage-savings)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Oral Small-molecule GLP-1 Receptor Agonists

<a id="topic-2.2.2.1.4-1"></a>

###### Orforglipron: FDA approval in April 2026

> “INDIANAPOLIS, April 1, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for adults with obesity, or overweight with weight-related medical problems.”
> “Foundayo™ (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity. Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day without restrictions on food and water intake.”

Source: [Eli Lilly Foundayo approval announcement (2026)](https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill)

<a id="topic-2.2.2.1.4-2"></a>

###### Orforglipron: FDA-approved indication and limitation of use

> “to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.”
> “Concomitant use with another GLP-1 receptor agonist is not recommended.”

Source: [Eli Lilly Foundayo prescribing information (2026)](https://uspl.lilly.com/foundayo/foundayo.html)

<a id="topic-2.2.2.1.4-3"></a>

###### Orforglipron: administration with or without food and dosage escalation

> “Take FOUNDAYO orally once daily, with or without food.”
> “The starting dosage is 0.8 mg orally once daily. After at least 30 days on the 0.8 mg dosage, increase the dosage to 2.5 mg once daily.”
> “After at least 30 days on the 2.5 mg dosage, increase the dosage to 5.5 mg once daily.”
> “The maximum dosage of FOUNDAYO is 17.2 mg once daily.”

Source: [Eli Lilly Foundayo prescribing information (2026)](https://uspl.lilly.com/foundayo/foundayo.html)

<a id="topic-2.2.2.1.4-4"></a>

###### Orforglipron: dosage modification with CYP3A4 inhibitors and inducers

> “Avoid strong CYP3A4 inhibitors that also inhibit OATP1B when taking FOUNDAYO.”
> “The maximum dosage of FOUNDAYO is 9 mg once daily when used concomitantly with a strong CYP3A4 inhibitor”
> “Avoid strong CYP3A4 inducers when taking FOUNDAYO.”

Source: [Eli Lilly Foundayo prescribing information (2026)](https://uspl.lilly.com/foundayo/foundayo.html)

<a id="topic-2.2.2.1.4-5"></a>

###### Orforglipron: design and treatment discontinuation in the labeled trial of adults without diabetes

> “In Trial 1 patients were randomized in a 3:3:3:4 ratio to FOUNDAYO 5.5 mg once daily, 9 mg once daily, 17.2 mg once daily, or placebo once daily.”
> “The proportions of patients who discontinued trial drug in Trial 1 were 22%, 22%, and 24% for the 5.5 mg, 9 mg, and 17.2 mg once daily FOUNDAYO-treated groups, respectively, and 30% for the placebo-treated group.”

Source: [Eli Lilly Foundayo prescribing information (2026)](https://uspl.lilly.com/foundayo/foundayo.html)

<a id="topic-2.2.2.1.4-6"></a>

###### Orforglipron: equivalence of trial capsule doses to approved tablet doses

> “The investigational capsule formulations of orforglipron (6 mg, 12 mg, and 36 mg) used in these trials are bioequivalent to the tablet doses (5.5 mg, 9 mg, and 17.2 mg)”

Source: [Horn et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13453602/)

<a id="topic-2.2.2.1.4-7"></a>

###### Orforglipron: weight change in adults aged 65 years and older

> “In ATTAIN-1 and ATTAIN-2, 616 randomized participants were ≥65 years of age.”
> “At Week 72, the percent change in weight from baseline among participants from ATTAIN-1 was −7.9% (95% CI: −10.0, –5.9), −11.3% (−13.4, −9.3), and −13.0% (−15.7, −10.4) with orforglipron 5.5 mg, 9 mg, and 17.2 mg, respectively, vs. −1.6% (−3.2, 0.1) with placebo (all p < 0.001)”

Source: [Horn et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13453602/)

<a id="topic-2.2.2.1.4-8"></a>

###### Orforglipron: self-pay, commercial, and Medicare Part D prices

> “Eligible people with commercial insurance may pay as little as $25 per month with the Foundayo savings card.”
> “Individuals opting for self-pay can access Foundayo starting at $149 per month for the lowest dose. Additionally, eligible Medicare Part D individuals may be able to get Foundayo for $50 per month, beginning as soon as July 1, 2026.”

Source: [Eli Lilly Foundayo approval announcement (2026)](https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill)

Additional sources: [Eli Lilly Foundayo coverage and savings (2026)](https://foundayo.lilly.com/hcp/savings-coverage)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Other Anti-obesity Medications

<a id="topic-2.2.2.1.5-1"></a>

###### AGA guideline recommendations for pharmacotherapy

> “The panel strongly recommended the use of pharmacotherapy in addition to lifestyle intervention in adults with overweight and obesity (body mass index ≥30 kg/m2, or ≥27 kg/m2 with weight-related complications) who have an inadequate response to lifestyle interventions.”
> “The panel suggested the use of semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate ER, and naltrexone-bupropion ER (based on moderate certainty evidence), and phentermine and diethylpropion (based on low certainty evidence), for long-term management of overweight and obesity.”
> “The guideline panel suggested against the use of orlistat.”

Source: [Grunvald et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36273831/)

<a id="topic-2.2.2.1.5-2"></a>

###### Endocrine Society guideline on medications as adjuncts to lifestyle change

> “Medications approved for chronic weight management can be useful adjuncts to lifestyle change for patients who have been unsuccessful with diet and exercise alone.”

Source: [Apovian et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25590212/)

<a id="topic-2.2.2.1.5-3"></a>

###### Weight loss with older anti-obesity medications in the ADA Standards of Care

| Medication | Active treatment arm; weight loss from baseline | Placebo; weight loss from baseline | Trial duration (weeks) |
| --- | --- | --- | --- |
| Phentermine | “15 mg q.d.; 7.4%” | “Placebo; 2.3%” | “28” |
| Phentermine/topiramate ER | “15 mg/92 mg q.d.; 9.8%” | “Placebo; 1.2%” | “56” |
| Naltrexone/bupropion ER | “16 mg/180 mg b.i.d.; 5%” | “Placebo; 1.8%” | “56” |
| Orlistat | “120 mg t.i.d.; 9.6%” | “Placebo; 5.6%” | “52” |

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/)

<a id="topic-2.2.2.1.5-4"></a>

###### Duration of approval for phentermine and other older adrenergic agents

> “Phentermine and other older adrenergic agents are approved for short-term treatment (112), while all others are approved for long-term treatment (Tables 8.1 and 8.2).”
> “As monotherapy, phentermine is only approved for short-term use.”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/)

<a id="topic-2.2.2.1.5-5"></a>

###### Phentermine plus topiramate: CONQUER primary results at week 56

> “At 56 weeks, change in bodyweight was -1·4 kg (least-squares mean -1·2%, 95% CI -1·8 to -0·7), -8·1 kg (-7·8%, -8·5 to -7·1; p<0·0001), and -10·2 kg (-9·8%, -10·4 to -9·3; p<0·0001) in the patients assigned to placebo, phentermine 7·5 mg plus topiramate 46·0 mg, and phentermine 15·0 mg plus topiramate 92·0 mg, respectively.”
> “The most common adverse events were dry mouth (24 [2%], 67 [13%], and 207 [21%] in the groups assigned to placebo, phentermine 7·5 mg plus topiramate 46·0 mg, and phentermine 15·0 mg plus topiramate 92·0 mg, respectively), paraesthesia (20 [2%], 68 [14%], and 204 [21%], respectively)”

Source: [Gadde et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21481449/)

<a id="topic-2.2.2.1.5-6"></a>

###### Naltrexone plus bupropion: COR-I primary results at week 56

> “Mean change in bodyweight was -1.3% (SE 0.3) in the placebo group, -6.1% (0.3) in the naltrexone 32 mg plus bupropion group (p<0.0001 vs placebo) and -5.0% (0.3) in the naltrexone 16 mg plus bupropion group (p<0.0001 vs placebo).”
> “870 (50%) participants completed 56 weeks of treatment (n=296; n=284; n=290, respectively)”

Source: [Greenway et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20673995/)

Additional sources: [Torgerson et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/14693982/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Metabolic and Bariatric Surgery

<a id="topic-2.2.2.1.6-1"></a>

###### ASMBS and IFSO indications for metabolic and bariatric surgery

> “Metabolic and bariatric surgery (MBS) is recommended for individuals with a body mass index (BMI) >35 kg/m2, regardless of presence, absence, or severity of co-morbidities.”
> “MBS should be considered for individuals with metabolic disease and BMI of 30-34.9 kg/m2.”
> “BMI thresholds should be adjusted in the Asian population such that a BMI > 25 kg/m2 suggests clinical obesity, and individuals with BMI > 27.5 kg/m2 should be offered MBS.”
> “Long-term results of MBS consistently demonstrate safety and efficacy.”

Source: [Eisenberg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9834364/)

<a id="topic-2.2.2.1.6-2"></a>

###### ADA recommendations for metabolic surgery in type 2 diabetes

> “Consider metabolic surgery as a weight and glycemic management approach in people with type 2 diabetes with BMI ≥30.0 kg/m2 (or ≥27.5 kg/m2 in Asian American individuals) who are otherwise good surgical candidates.”
> “People who undergo metabolic surgery should receive long-term medical and behavioral support and routine micronutrient, nutritional, and metabolic status monitoring.”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/)

<a id="topic-2.2.2.1.6-3"></a>

###### Perioperative mortality and complications

> “Perioperative mortality rates are typically 0.1–0.5%, similar to those for common abdominal procedures such as cholecystectomy and hysterectomy (149,150). Major complications occur in 2–6% of those undergoing metabolic surgery, which compares favorably with the rates for other commonly performed elective operations (150).”
> “Minor complications and need for operative reintervention occur in up to 15% (149,151–153).”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/)

<a id="topic-2.2.2.1.6-4"></a>

###### Long-term survival after metabolic-bariatric surgery

> “In the overall population consisting 174 772 participants, metabolic-bariatric surgery was associated with a reduction in hazard rate of death of 49·2% (95% CI 46·3-51·9, p<0·0001) and median life expectancy was 6·1 years (95% CI 5·2-6·9) longer than usual care.”

Source: [Syn et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33965067/)

<a id="topic-2.2.2.1.6-5"></a>

###### Long-term follow-up after surgery

> “Multiple studies have demonstrated that long-term follow up with the surgical team reduces drastically to 30 % in two years and less than 10 % in 10 years”

Source: [Pennings et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11997402/)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Limitations of Current Therapies

<a id="topic-2.2.2.1.7-1"></a>

###### Summary: limitations of current therapies

In the STEP 1 extension, participants who stopped semaglutide 2.4 mg at week 68 regained 11.6 of 17.3 percentage points of lost weight by week 120. In SURMOUNT-4 (670 randomized participants), those switched from tirzepatide to placebo regained 14% of body weight over 52 weeks, while those who continued tirzepatide lost a further 5.5%. A 2026 meta-analysis of 37 studies (9,341 participants) estimated weight regain of 0.4 kg per month after cessation of weight management medication, with cardiometabolic markers projected to return to baseline within 1.4 years. In commercial claims, 1-year persistence among adults without diabetes was 32.3% for initiators in 2021 and 60.9% for initiators of semaglutide (Wegovy) or tirzepatide (Zepbound) in the first half of 2024; the later study states that shortage resolution “may have improved persistence rates”. In a health-system cohort, 1-year discontinuation was 64.8% in adults without type 2 diabetes. ICER states that “there are few data from clinical trials on outcomes beyond 2-3 years” and that there “remain challenges to accessing highly effective obesity medications”. In a 2025 employer survey, 49% of large employers covered GLP-1 medications for weight loss. In the ADA table of older agents, weight loss from baseline was 5% to 9.8% with active treatment and 1.2% to 5.6% with placebo; phentermine is approved only for short-term use; and metabolic surgery carries perioperative mortality of 0.1% to 0.5% with long-term follow-up by the surgical team falling to 30% at two years.

Source: [Wilding et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252/); [Aronne et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10714284/); [West et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12776922/); [Gleason et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11293763/); [Marshall et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948759/); [Rodriguez et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11786232/); [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf); [Mercer (2025)](https://www.mercer.com/en-us/about/newsroom/employers-and-workers-face-affordability-crunch-as-health-insurnace-cost-is-expected-to-exceed-18500-per-employee-in-2026/); [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/); [Pennings et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11997402/)

<a id="topic-2.2.2.1.7-2"></a>

###### Weight regain after withdrawal of semaglutide 2.4 mg in the STEP 1 extension

> “From week 0 to week 68, mean weight loss was 17.3% (SD: 9.3%) with semaglutide and 2.0% (SD: 6.1%) with placebo. Following treatment withdrawal, semaglutide and placebo participants regained 11.6 (SD: 7.7) and 1.9 (SD: 4.8) percentage points of lost weight, respectively, by week 120, resulting in net losses of 5.6% (SD: 8.9%) and 0.1% (SD: 5.8%), respectively, from week 0 to week 120.”
> “Cardiometabolic improvements seen from week 0 to week 68 with semaglutide reverted towards baseline at week 120 for most variables.”

Source: [Wilding et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252/)

<a id="topic-2.2.2.1.7-3"></a>

###### Weight regain after withdrawal of tirzepatide in SURMOUNT-4

> “After 36 weeks of open-label maximum tolerated dose of tirzepatide (10 or 15 mg), adults (n = 670) with obesity or overweight (without diabetes) experienced a mean weight reduction of 20.9%. From randomization (at week 36), those switched to placebo experienced a 14% weight regain and those continuing tirzepatide experienced an additional 5.5% weight reduction during the 52-week double-blind period.”

Source: [Aronne et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10714284/)

<a id="topic-2.2.2.1.7-4"></a>

###### Rate of weight regain after cessation of weight management medications

> “Of the 9288 titles screened, 37 studies (63 intervention arms, 9341 participants) were included.”
> “The average monthly rate of weight regain was 0.4 kg (95% confidence interval (CI) 0.3 to 0.5) (mixed model 0.3 kg (0.2 to 0.4) monthly v control in RCTs). All cardiometabolic markers were projected to return to baseline within 1.4 years after the cessation of WMM. Weight regain was faster after WMM than after BWMP (by 0.3 kg (0.22 to 0.34) monthly), independent of initial weight loss.”

Source: [West et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12776922/)

<a id="topic-2.2.2.1.7-5"></a>

###### Real-world persistence and adherence in commercially insured adults without diabetes

> “Overall, GLP-1 persistence was 46.3% at 180 days and 32.3% at 1 year. The highest and lowest persistence rates at 1 year were observed for semaglutide (Ozempic) at 47.1% and liraglutide (Saxenda) 19.2%, respectively. Average PDC during the 1-year assessment was 51.0% with 27.2% adherent to therapy and 11.1% switched GLP-1 drugs.”

Source: [Gleason et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11293763/)

<a id="topic-2.2.2.1.7-6"></a>

###### Persistence trend by year of initiation and drug shortages

> “Across the index years, 1-year persistence increased from 33.2% in 2021 to 60.9% in 1H 2024.”
> “For tirzepatide, 1-year persistence rates in 2023 and 1H 2024 (the only years the product was available) were 64.0% and 64.8%, respectively.”
> “GLP-1RA product shortage resolution may have improved persistence rates.”

Source: [Marshall et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948759/)

<a id="topic-2.2.2.1.7-7"></a>

###### Discontinuation in adults with obesity without type 2 diabetes

> “Patients with obesity only had a higher prevalence of discontinuation at 12 months vs those with T2D only and those with both (50.3% vs 35.8% and 34.2%).”

Source: [Do et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11127113/)

> “One-year discontinuation was significantly higher for patients without type 2 diabetes (64.8% [95% CI, 64.4%-65.2%]) compared with those with type 2 diabetes (46.5% [95% CI, 46.2%-46.9%]).”
> “moderate or severe incident gastrointestinal adverse events were associated with a higher hazard of discontinuation (with type 2 diabetes: HR, 1.38 [95% CI, 1.31-1.45]; without type 2 diabetes: HR, 1.19 [95% CI, 1.12-1.27]).”

Source: [Rodriguez et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11786232/)

<a id="topic-2.2.2.1.7-8"></a>

###### Discontinuation for adverse events with injectable incretin therapy

> “A higher proportion of the trial participants receiving semaglutide (8%) discontinued treatment due to adverse events compared to tirzepatide (6%). More participants receiving semaglutide (5.6%) discontinued treatment due to GI-related side effects than those receiving tirzepatide (2.7%).”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-2.2.2.1.7-9"></a>

###### Limited long-term outcome and safety data

> “Obesity is a lifelong disease; however, there are a lack of long-term follow-up data for both benefits and harms. For example, there are few data from clinical trials on outcomes beyond 2-3 years, particularly for weight maintenance.”
> “However, we do not yet have data on the impact of discontinuation on other outcomes (e.g., risk of CV events, progression of MASH or CKD, etc.) or data on whether re-treatment in the future conveys the same benefits as initial treatment.”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-2.2.2.1.7-10"></a>

###### Access to obesity medications and comprehensive care

> “Despite the number of therapies available, there remain challenges to accessing highly effective obesity medications and thus additional options for treatment may be beneficial in closing the treatment gap.”
> “Coupled with the uneven and restricted insurance coverage of obesity medications, very few individuals living with obesity could be considered as having access to comprehensive and affordable obesity care.”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-2.2.2.1.7-11"></a>

###### Employer coverage of GLP-1 medications for weight loss

> “Notably, more large employers covered costly GLP-1 weight-loss medications in 2025 – 49%, up from 44% in 2024.”

Source: [Mercer (2025)](https://www.mercer.com/en-us/about/newsroom/employers-and-workers-face-affordability-crunch-as-health-insurnace-cost-is-expected-to-exceed-18500-per-employee-in-2026/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary: anticipated place in treatment

VK2735 is investigational and has no approved indication. Guidelines place anti-obesity pharmacotherapy as an adjunct to lifestyle intervention: the AGA strongly recommends pharmacotherapy in addition to lifestyle intervention for adults with BMI of 30 or higher, or 27 or higher with weight-related complications, who have an inadequate response to lifestyle interventions, and the ADA names semaglutide or tirzepatide as the preferred agents for people with diabetes and overweight or obesity. The WHO guideline describes obesity as requiring “lifelong care”. The OMA and ACOFP describe family physicians as “often the first line of treatment”, and ICER expects that “much of the treatment of obesity, including prescribing medications, will be done by primary care clinicians”. Viking describes the subcutaneous formulation as suited to weight maintenance with every-other-week or monthly dosing after weekly induction, and the VANQUISH-1 extension will include these less-frequent regimens, with results anticipated in 2028. Viking describes the oral tablet as positioned to become the first oral dual GLP-1/GIP agonist to reach the market and expects many initial users of oral therapies to transition to subcutaneous administration. In a May 2024 national poll, 12% of U.S. adults reported ever taking a GLP-1 agonist and 6% reported current use.

Source: [Grunvald et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36273831/); [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/); [Celletti et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41324410/); [Pennings et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11997402/); [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf); [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/); [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update); [Montero et al. (2024)](https://www.kff.org/health-costs/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/)

<a id="topic-2.2.2.2-2"></a>

###### Preferred pharmacotherapy in people with diabetes and overweight or obesity

> “Obesity pharmacotherapy should be considered for people with diabetes and overweight or obesity along with lifestyle changes. Potential benefits and risks must be considered.”
> “In people with diabetes and overweight or obesity, the preferred pharmacotherapy should be a glucagon-like peptide 1 receptor agonist or dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist with greater weight loss efficacy (i.e., semaglutide or tirzepatide)”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/)

<a id="topic-2.2.2.2-3"></a>

###### Obesity as a chronic disease requiring lifelong care

> “The guidelines recognize obesity as a chronic, relapsing disease requiring lifelong care and emphasize early diagnosis and integrated, person-centered approaches combining behavioral, medical, surgical, and other interventions alongside prevention and management of comorbidities.”

Source: [Celletti et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41324410/)

<a id="topic-2.2.2.2-4"></a>

###### Primary care as the care setting

> “Family physicians are often the first line of treatment in the healthcare setting.”
> “Barriers that impede optimal care of patients with obesity in primary care include failure to recognize obesity as a disease, lack of accurate diagnosis, insufficient access to obesity treatment resources, inadequate training, insufficient time, lack of adequate reimbursement and the adverse impact of bias, stigma, and discrimination.”

Source: [Pennings et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11997402/)

> “Given the large size of the population affected by obesity, much of the treatment of obesity, including prescribing medications, will be done by primary care clinicians.”
> “there is a shortage of primary care physicians who are knowledgeable about treatment of obesity as well as an extreme shortage of obesity medicine specialists”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-2.2.2.2-5"></a>

###### Subcutaneous formulation: manufacturer positioning for weight maintenance

> “As we have discussed previously, VK2735 has a unique and differentiated profile that we believe may accommodate less frequent dosing compared to standard weekly dosing, making it uniquely suited for the maintenance setting.”
> “Importantly, by using the same therapeutic agent for both the initial weight loss and for the long-term maintenance phase of weight management, we believe patients may experience reduced side effects compared with options that require switching between different therapeutic agents.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-2.2.2.2-6"></a>

###### Subcutaneous formulation: less-frequent dosing regimens in the VANQUISH-1 extension

> “In addition, the VANQUISH-1 extension study will include certain less-frequent dosing regimens, including every-other-week and monthly administration. The company anticipates the results of the extension studies to be available in 2028.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-2.2.2.2-7"></a>

###### Oral formulation: manufacturer positioning

> “If successful, the tablet formulation is positioned to become the first oral dual GLP-1/GIP agonist to reach the market.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “As clinicians and patients continue to seek flexibility in formulations and dosing, we believe oral VK2735 may represent another differentiated and high-value tool in their treatment toolbox.”
> “What we are seeing right now with the oral therapies is sort of a market expansion. We expect a lot of those initial users to likely transition to the subQ route of administration to achieve even greater weight loss than they have experienced with the initial oral experience.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-2.2.2.2-8"></a>

###### Oral and subcutaneous formulations: manufacturer positioning on dosing flexibility

> “The potential availability of both a tablet and a subcutaneous formulation, across a variety of dosing regimens, will offer unmatched optionality and flexibility to best support a personalized and sustainable weight loss journey.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

> “Having the ability to dose weekly, every other week, or monthly, I think imparts flexibility that others cannot offer at this point and we do not see in the market today.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-2.2.2.2-9"></a>

###### Use of GLP-1 agonists among U.S. adults

> “The latest KFF Health Tracking Poll finds that about one in eight adults (12%) say they have ever taken a GLP-1 agonist”
> “including 6% who say they are currently taking such a drug”

Source: [Montero et al. (2024)](https://www.kff.org/health-costs/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Subgroup assessment for semaglutide and tirzepatide in the ICER review

> “We did not find evidence of major differences in the balance of benefits and risks for the following subgroups: age, sex at birth, race and ethnicity, BMI categories, use and intensity of lifestyle interventions, established CV disease, and prior bariatric surgery.”
> “Tirzepatide also demonstrated consistent percent changes in body weight from baseline versus placebo in BMI-defined subgroups (BMI <30, BMI 30-35, BMI 35-40, and BMI >40).”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-2.2.2.3-2"></a>

###### Race and ethnicity: representation and weight loss in incretin trials

> “Although subgroup analysis did not show statistically significant differences in weight loss by sex and race/ethnicity in post-hoc analyses of the STEP trials, Black, Hispanic, and Asian participants had numerically less weight loss than White participants.”
> “Given the underrepresentation of Black and Hispanic populations in the STEP and SURMOUNT trials, additional data are needed to ascertain if there may be differences in outcome by subgroup.”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-2.2.2.3-3"></a>

###### Sex, age, and region: semaglutide 2.4 mg in SELECT

> “Women had a greater difference in mean weight loss with semaglutide versus placebo (−11.1% (95% CI −11.56 to −10.66) versus −7.5% in men (95% CI −7.78 to −7.23); P < 0.0001).”
> “There was a linear relationship between age category and degree of mean weight loss, with younger age being associated with progressively greater mean weight loss, but the actual mean difference by age group is small.”
> “Patients from Asia and of Asian race experienced slightly lower mean weight loss (estimated treatment difference with semaglutide for Asian race −7.27% (95% CI −8.09 to −6.46; P = 0.0147) and for Asia −7.30 (95% CI −7.97 to −6.62; P = 0.0016)).”

Source: [Ryan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11271387/)

<a id="topic-2.2.2.3-4"></a>

###### Reproductive stage: tirzepatide in women in SURMOUNT-1

> “In SURMOUNT‐1, significantly greater body weight reductions from baseline were observed with tirzepatide versus placebo in women in the premenopause (26% vs. 2%), perimenopause (23% vs. 3%), and postmenopause stages (23% vs. 3%; p < 0.001).”

Source: [Tchang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12015656/)

<a id="topic-2.2.2.3-5"></a>

###### Diabetes status: tirzepatide in SURMOUNT-1, adults without diabetes

> “The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo”

Source: [Jastreboff et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35658024/)

<a id="topic-2.2.2.3-6"></a>

###### Diabetes status: tirzepatide in SURMOUNT-2, adults with type 2 diabetes

> “Least-squares mean change in bodyweight at week 72 with tirzepatide 10 mg and 15 mg was -12·8% (SE 0·6) and -14·7% (0·5), respectively, and -3·2% (0·5) with placebo”

Source: [Garvey et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37385275/)

<a id="topic-2.2.2.3-7"></a>

###### Diabetes status: semaglutide 7.2 mg in STEP UP, adults without diabetes

> “The mean change in bodyweight was greater with semaglutide 7·2 mg versus 2·4 mg (-18·7% [SE 0·4] vs -15·6% [0·7]; estimated treatment difference [ETD] -3·1% [95% CI -4·7 to -1·6]; p<0·0001) and with semaglutide 7·2 mg versus placebo (-18·7% [0·4] vs -3·9% [0·6]; -14·8% [-16·2 to -13·4]; p<0·0001).”

Source: [Wharton et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/40961952/)

<a id="topic-2.2.2.3-8"></a>

###### Diabetes status: semaglutide 7.2 mg in STEP UP T2D, adults with type 2 diabetes

> “Compared with placebo, semaglutide 7·2 mg led to greater reductions in mean bodyweight (-13·2% vs -3·9%; estimated treatment difference [ETD] -9·3% [95% CI -11·0 to -7·7]; p<0·0001)”

Source: [Lingvay et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40961953/)

<a id="topic-2.2.2.3-9"></a>

###### Age 65 years and older: oral orforglipron in ATTAIN-1 and ATTAIN-2

> “At Week 72, the percent change in weight from baseline among participants from ATTAIN-1 was −7.9% (95% CI: −10.0, –5.9), −11.3% (−13.4, −9.3), and −13.0% (−15.7, −10.4) with orforglipron 5.5 mg, 9 mg, and 17.2 mg, respectively, vs. −1.6% (−3.2, 0.1) with placebo (all p < 0.001)”
> “Comparable findings were observed in participants <65 years of age.”

Source: [Horn et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13453602/)

<a id="topic-2.2.2.3-10"></a>

###### Subcutaneous formulation: BMI category change by baseline obesity class in VENTURE

| Baseline BMI category | VK2735 participants (n) | Placebo participants (n) | VK2735: no change in obesity class | Placebo: no change in obesity class |
| --- | --- | --- | --- | --- |
| Class III obesity | “n=35” | “n=15” | “31 %” | “87 %” |
| Class II obesity | “n=51” | “n=10” | “18 %” | “80 %” |
| Class I obesity | “n=46” | “n=8” | “26 %” | “75%” |

Source: [Viking Therapeutics ObesityWeek 2026 release (2026)](https://ir.vikingtherapeutics.com/2026-11-15-Viking-Therapeutics-Highlights-Clinical-Data-from-VK2735-Obesity-Program-at-ObesityWeek-R-2026)

<a id="topic-2.2.2.3-11"></a>

###### Diabetes status: survival after metabolic-bariatric surgery

> “In subgroup analyses, both individuals with (hazard ratio 0·409, 95% CI 0·370-0·453, p<0·0001) or without (0·704, 0·588-0·843, p<0·0001) baseline diabetes who underwent metabolic-bariatric surgery had lower rates of all-cause mortality, but the treatment effect was considerably greater for those with diabetes (between-subgroup I2 95·7%, p<0·0001).”

Source: [Syn et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33965067/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Coverage criteria recommended by ICER for incretin anti-obesity medications

> “Payers could follow the example of the proposed criteria for Medicare coverage: 1) BMI ≥ 27 with prediabetes or established CV disease, 2) BMI ≥ 30 with uncontrolled hypertension, kidney disease, or heart failure, 3) BMI ≥ 35.”
> “Payers should consider having prior authorization approval apply to all doses, rather than require prior authorization for each dose separately, to minimize burden on prescribers and patients.”
> “Initial coverage will likely be for a period of 12 months, which is long enough for dose titration, assessment of side effects, and assessment of efficacy.”
> “Renewal of therapy: Payers should use a patient’s starting weight, not current weight, as the basis for judging whether further treatment is necessary.”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-2.2.2.4-2"></a>

###### Step therapy and preferred formulary options

> “Because of the budget impact of injectable semaglutide and tirzepatide, payers may still wish to employ step therapy, requiring enrollment in structured obesity management programs and/or trying less expensive medications.”
> “There is no justification for payers to make patients re-try weight loss programs or medications that they have previously tried and that have failed them.”
> “Payers may opt to have one drug from the newer GLP-1 RA class as the preferred formulary option.”
> “if there is a preferred formulary option, payers should have a rapid exceptions process for patients to switch to or continue the non-preferred option.”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-2.2.2.4-3"></a>

###### Medicare GLP-1 Bridge demonstration

> “The Medicare GLP-1 Bridge is a short-term demonstration run by CMS that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027.”
> “In 2026, CMS will use a single central processor to manage prior authorization, claims adjudication, and payment to pharmacies for the Medicare GLP-1 Bridge.”
> “Eligible beneficiaries will have a $50 copay.”
> “This means that the Part D deductible will not apply, no part of the $50 copay counts towards the beneficiary’s TrOOP costs, and there is no low-income subsidy (LIS) provided for LIS beneficiaries.”

Source: [CMS Medicare GLP-1 Bridge (2026)](https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge)

<a id="topic-2.2.2.4-4"></a>

###### BALANCE Model: negotiated prices, lifestyle support, and product eligibility

> “Under BALANCE, CMS negotiates lower prices directly with eligible GLP-1 manufacturers on behalf of State Medicaid agencies and Part D plans. Negotiations also address eligibility criteria for patients.”
> “All beneficiaries receiving GLP-1s for weight management under the BALANCE model in Medicaid will be provided with access to a lifestyle support program, provided by the manufacturer at no cost.”
> “Patients would be subject to qualifications set by the negotiations between CMS and participating manufacturers, including certain prior authorization requirements.”
> “Eligible manufacturers are those that are eligible for the initial negotiations or expect to market an eligible product by January 1, 2027.”
> “have clinical evidence that, at an FDA-approved dose, the product reduces body weight by at least 9.5% on average, according to the primary or secondary endpoint in a randomized clinical trial”
> “All formulations of Mounjaro®, Ozempic®, Rybelsus®, and Wegovy®, the KwikPen formulation of Zepbound®, and Foundayo™.”

Source: [CMS BALANCE Model (2026)](https://www.cms.gov/priorities/innovation/innovation-models/balance)

<a id="topic-2.2.2.4-5"></a>

###### Structured behavioral programs alongside pharmacotherapy

> “Interventions that combined pharmacotherapy with behavioral interventions reported greater weight loss and weight loss maintenance”

Source: [US Preventive Services Task Force (2018)](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/obesity-in-adults-interventions)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Cardiovascular events: semaglutide 2.4 mg in SELECT

> “A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001).”
> “Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001).”

Source: [Lincoff et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37952131/)

<a id="topic-2.2.2.7-2"></a>

###### Weight loss sustained to 4 years in SELECT

> “In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years. At 208 weeks, semaglutide was associated with mean reduction in weight (−10.2%), waist circumference (−7.7 cm) and waist-to-height ratio (−6.9%) versus placebo (−1.5%, −1.3 cm and −1.0%, respectively; P < 0.0001 for all comparisons versus placebo).”

Source: [Ryan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11271387/)

<a id="topic-2.2.2.7-3"></a>

###### Progression to type 2 diabetes: tirzepatide over 176 weeks in SURMOUNT-1

> “At 176 weeks, the mean percent change in body weight among the participants who received tirzepatide was -12.3% with the 5-mg dose, -18.7% with the 10-mg dose, and -19.7% with the 15-mg dose, as compared with -1.3% among those who received placebo (P<0.001 for all comparisons with placebo).”
> “Fewer participants received a diagnosis of type 2 diabetes in the tirzepatide groups than in the placebo group (1.3% vs. 13.3%; hazard ratio, 0.07; 95% confidence interval [CI], 0.0 to 0.1; P<0.001).”

Source: [Jastreboff et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39536238/)

<a id="topic-2.2.2.7-4"></a>

###### Obstructive sleep apnea: tirzepatide in SURMOUNT-OSA

> “In trial 1, the mean change in AHI at week 52 was −25.3 events per hour (95% confidence interval [CI], −29.3 to −21.2) with tirzepatide and −5.3 events per hour (95% CI, −9.4 to −1.1) with placebo, for an estimated treatment difference of −20.0 events per hour (95% CI, −25.8 to −14.2) (P<0.001).”
> “In trial 2, the mean change in AHI at week 52 was −29.3 events per hour (95% CI, −33.2 to −25.4) with tirzepatide and −5.5 events per hour (95% CI, −9.9 to −1.2) with placebo, for an estimated treatment difference of −23.8 events per hour (95% CI, −29.6 to −17.9) (P<0.001).”

Source: [Malhotra et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11598664/)

<a id="topic-2.2.2.7-5"></a>

###### Heart failure with preserved ejection fraction: semaglutide 2.4 mg in STEP-HFpEF

> “The mean change in the KCCQ-CSS was 16.6 points with semaglutide and 8.7 points with placebo (estimated difference, 7.8 points; 95% confidence interval [CI], 4.8 to 10.9; P<0.001), and the mean percentage change in body weight was -13.3% with semaglutide and -2.6% with placebo (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001).”
> “The mean change in the 6-minute walk distance was 21.5 m with semaglutide and 1.2 m with placebo (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001).”

Source: [Kosiborod et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37622681/)

<a id="topic-2.2.2.7-6"></a>

###### Steatohepatitis: semaglutide 2.4 mg in ESSENCE

> “Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the 534 patients in the semaglutide group and in 34.3% of the 266 patients in the placebo group (estimated difference, 28.7 percentage points; 95% confidence interval [CI], 21.1 to 36.2; P<0.001).”
> “A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group (estimated difference, 14.4 percentage points; 95% CI, 7.5 to 21.3; P<0.001).”

Source: [Sanyal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40305708/)

<a id="topic-2.2.2.7-7"></a>

###### Glycemic outcomes associated with 5% to 10% weight loss

> “Weight loss of 5% to 10% is associated with hemoglobin A1c reductions of 0.6% to 1.0% and reduced need for diabetes medications.”

Source: [Jensen et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5819889/)

<a id="topic-2.2.2.7-8"></a>

###### Health care spending associated with weight loss

> “In this cross-sectional study of 17 209 adults, among those with employer-sponsored insurance, adults with a baseline BMI of 30 were estimated to spend 7% less following the loss of 5% of BMI and 30% less following the loss of 25% of BMI. Similar results were found for Medicare adults.”

Source: [Thorpe and Joski (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11621981/)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
